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ABSTRACT
The inability to maintain genomic stability and control proliferation are
hallmarks of many cancers, which become exacerbated in the presence of unrepaired
DNA damage. Such genotoxic stresses trigger the p53 tumor suppressor network to
activate transient cell cycle arrest allowing for DNA repair; if the damage is excessive or
irreparable, apoptosis or cellular senescence is triggered. One of the major DNA repair
pathway that mends DNA double strand breaks is non-homologous end joining (NHEJ).
Abrogating the NHEJ pathway leads to an accumulation of DNA damage in the
lymphoid system that triggers p53-mediated apoptosis; complete deletion of p53 in this
system leads to aggressive lymphomagenesis. Therefore, to study the effect of p53dependent cell cycle arrest, we utilized a hypomorphic, separation-of-function mutant,
p53p/p, which completely abrogates apoptosis yet retains partial cell cycle arrest ability.
We crossed DNA ligase IV deficiency, a downstream ligase crucial in mending breaks
during NHEJ, into the p53p/p background (Lig4-/-p53p/p). The accumulation of DNA
damage activated the p53/p21 axis to trigger cellular senescence in developing lymphoid
cells, which absolutely suppressed tumorigenesis. Interestingly, these mice progressively
succumb to severe diabetes. Mechanistic analysis revealed that spontaneous DNA
damage accumulated in the pancreatic -cells, a unique subset of endocrine cells solely
responsible for insulin production to regulate glucose homeostasis. The genesis of adult
-cells predominantly occurs through self-replication, therefore modulating cellular
proliferation is an essential component for renewal. The progressive accumulation of
DNA damage, caused by Lig4-/-, activated p53/p21-dependent cellular senescence in
mutant pancreatic -cells that lead to islet involution. Insulin levels subsequently

vi

decreased, deregulating glucose homeostasis driving overt diabetes. Our Lig4-/-p53p/p
model aptly depicts the dichotomous role of cellular senescence—in the lymphoid
system prevents tumorigenesis yet in the endocrine system leads to the decrease of
insulin-producing cells causing diabetes.
To further delineate the function of NHEJ in pancreatic -cells, we analyzed
mice deficient in another component of the NHEJ pathway, Ku70. Although most
notable for its role in DNA damage recognition and repair within the NHEJ pathway,
Ku70 has NHEJ-independent functions in telomere maintenance, apoptosis, and
transcriptional regulation/repression. To our surprise, Ku70-/-p53p/p mutant mice
displayed a stark increase in -cell proliferation, resulting in islet expansion, heightened
insulin levels and hypoglycemia. Augmented -cell proliferation was accompanied with
the stabilization of the canonical Wnt pathway, responsible for this phenotype.
Interestingly, the progressive onset of cellular senescence prevented islet tumorigenesis.
This study highlights Ku70 as an important modulator in not only maintaining genomic
stability through NHEJ-dependent functions, but also reveals a novel NHEJ-independent
function through regulation of pancreatic -cell proliferation. Taken in aggregate, these
studies underscore the importance for NHEJ to maintain genomic stability in -cells as
well as introduces a novel regulator for pancreatic -cell proliferation.
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CHAPTER 1
INTRODUCTION

1

1.1

The DNA Damage Response
Genomic instability occurs at all stages of cancers and is currently considered

one of the hallmarks of cancers worth attempting to target therapeutically (Hanahan &
Weinberg, 2011). Cells receive thousands of DNA lesions per day, which if not repaired,
or repaired incorrectly, can lead to disastrous mutations that can compromise cell
survival and proliferation rates (Jackson & Bartek, 2009). One of the most harmful
types of genomic damage is DNA double strand breaks (DSBs) which can lead to
chromosomal translocations and increase the propensity of cancers if left unrepaired.
DNA double strand breaks can be caused by a variety of different genotoxic stresses
such as gamma irradiation, oxidative stress, spontaneously, or through oncogenic
activation. Briefly, DNA breaks are detected by DNA damage sensors, which in turn
recruit the protein kinases Ataxia-telangiectasia mutated (ATM) or ATM and Rad3related kinase (ATR). These kinases phosphorylate and activate certain DNA-damage
mediators (examples include H2AX and 53bp1) as well as other downstream kinases
together that can help further amplify this multifaceted signaling response as well as
target downstream effectors like the tumor suppressor p53 ultimately stopping a
damaged cell from cycling (Campisi, 2005; Shiloh, 2003). The purpose of halting the
cell cycle, creating a checkpoint, is to allow time for DNA repair factors to fix the
damage.

These recruitment complexes bind to DNA and form foci, detectible by

immunofluorescence, indicating an activated damage response (Lukas et al, 2003). If
the damage is extensive or irreparable, the cell will initiate different cellular responses—
apoptosis, autophagy, or cellular senescence, yet the factors involving the decision
making to initiate such responses still remain unclear (d'Adda di Fagagna, 2008).

Pharmacological induction of DNA damage remains one of the pillar treatment for
cancer therapy, unfortunately, cancer cells can adapt by increasing the activity of their
DNA repair pathways (Bolderson et al, 2009). Collectively, this signaling cascade
devised to prevent the cell from promoting proliferation of damaged or mutated DNA, is
termed the DNA damage response (DDR).

Additionally, the DDR directly halts

transcription, activates autophagy for energy consumption, remodels chromatin, and
repair DNA to combat these dangerous DNA lesions (Jackson & Bartek, 2009). The
DNA damage response acts to repress tumorigenesis by activating downstream
molecules which, when mutated or deleted directly cause human diseases and multiple
cancer types (Meek, 2009). Due to the many different types of DNA damages, the cell
has devised multiple DNA repair pathways—base excision repair corrects abnormal
DNA bases; nucleotide excision repair fixes bulky adducts and ultraviolet-created
lesions; mismatch repair senses and replaces DNA mismatches and insertions or
deletions; and finally, both homologous recombination and non-homologous end joining
function to repair DNA double strand breaks (Jackson & Bartek, 2009).

1.2

Non-homologous end joining
Hallmark to almost all human cancers is genomic instability, which is

exacerbated in the presence of unrepaired DNA damage (Negrini et al, 2010). One of
the major repair pathways for DNA double strand breaks is non-homologous end joining
(NHEJ) functioning to fix open DNA ends (Mahaney et al, 2009). The main factors
involved in the NHEJ pathway are the end recognition/ processing complex composed of
a Ku70/80 heterodimer, DNA-PKcs, and repair factor Artemis, as well as the ligation

complex, functioning to join DSBs, consisting of DNA ligase IV (Lig4), XRCC4, and
Cernunnos/XLF (Figure 1). In mice, inactivation of any non-homologous end joining
factors besides Cernunnos/XLF result in severe combined immunodeficiency (SCID)
due to failed lymphocyte development (Puebla-Osorio & Zhu, 2008). Interestingly,
NHEJ deficient mice exhibit an accelerated aging phenotype and reports document the
decline of NHEJ functionality with age suggesting a link between the inability to repair
DNA upon age (Gorbunova et al, 2007). Notably, cells deficient in NHEJ factors lead to
clastogen hypersensitivity (i.e., ionizing radiation), obviously due to the inability to
repair breaks. Classically considered a caretaker tumorsuppressor, NHEJ has recently
been proposed to modulate gatekeeper functions, like p53, to prevent the persistence of
DNA DSBs that would otherwise lead to gross chromosomal rearrangements (Hasty,
2008). One example of this scenario is the deficiency of ligase IV or XRCC4, which
present embryonic lethality due to excessive p53-mediated neuronal apoptosis, which is
rescued by p53 deficiency (Frank et al, 1998; Frank et al, 2000; Gao et al, 2000).
Although surviving prenatally, these double deficiencies lead to early, aggressive pro-B
lymphomas due to chromosomal translocations predominantly involving chromosome
12 at the IgH locus and chromosome 15 near the proto-oncogene c-MYC (Gao et al,
1998; Zhu et al, 2002). It has been proposed, that targeting DNA repair pathways, such
as NHEJ, in concert with DNA damaging agents will increase treatment efficacy and
reduce off target effects because many tumors increase NHEJ factors. Cells deficient in
NHEJ factors are sensitive to chemotherapeutic agents that induce DSBs, thus
pharmacological inhibition of these molecules are showing promise and rapidly moving
into the clinical setting (Bolderson et al, 2009; Martin et al, 2008; Zhao et al, 2006).

A

B

C
XLF

D

Figure 1. Non-homologous end joining steps.
(A) Ku70 and Ku80 heterodimer forms and binds DNA double-strand breaks. (B)
DNA-PKcs is recruited and activated. (C) Repair factor Artemis is recruited and
activated to blunt DNA ends. The ligase complex composed of XRCC4, XLF, and
DNA Ligase IV is further recruited after DNA polymerase µ fills in gaps. (D) NHEJ
factors dissociate from repaired DNA.
(Modified and reproduced from (Xu, 2006) with permission from Nature Reviews
Immunology)

Classically, the factors involved in the non-homologous end joining pathway can
be compiled in two groups: the DNA end recognition/processing complex consisting of
the DNA-dependent kinase catalytic subunit (Ku70/80 heterodimer and DNA-PKcs) and
the DNA repair factor Artemis along with the DNA ligation complex (DNA Ligase IV,
XRCC4, Cernunnos/XLF)(Mahaney et al, 2009). Interestingly, viable NHEJ deficient
mice exhibit an accelerated aging phenotype, when taken together with reports
documenting the decline of NHEJ functionality with age, suggest a link between
impaired DNA repair and age.(Gorbunova et al, 2007)

1.3

Tumor Suppressor p53
Termed the ‘guardian of the genome’, p53 is best characterized as a transcription

factor that binds and transactivates genes to induce and balance a diverse network of
cellular functions including autophagy, apoptosis and cellular senescence (Vousden &
Prives, 2009).

Such cellular mechanisms are crucial in protecting the cell against

tumorigenesis in the presence of genotoxic stresses including DNA damage. Upon
sensing DNA damage, the DDR will activate the stress responsive protein p53 to arrest
cells from cycling, allowing time for DNA repair pathways to attempt the mend the
lesions. Upon excessive and irreparable DNA damage, p53 can trigger a signaling
cascade to induce apoptosis through transcription of different pro-apoptotic genes,
including PUMA (p53-upregulated modulator of apoptosis) and Noxa (Meek, 2009;
Vousden & Prives, 2009). Alternatively, p53 can induce irreversible cell-cycle arrest,
termed cellular senescence, halting the proliferation of damaged cells despite
stimulations with mitogenic factors (Campisi, 2005). Downstream target of p53 and

pivotal to the initiation of cell cycle arrest is the cyclin dependent kinase inhibitor p21
whose deletion leads to the bypass of senescence (Abbas & Dutta, 2009; Brown et al,
1997). By halting tumor proliferation, senescence acts in parallel to the apoptotic
pathway as barriers to tumor development/progression (Figure 2).
Due to the high mutation rate of p53 in both familial and somatic cancers, p53
has become one of the most studied genes and tumor suppressors. Many cancers mutate
or abolish p53 function, leaving cells vulnerable to replication after DNA damage which
translates into a state of crisis (Lavin & Gueven, 2006). Complete abrogation of p53
gives rise to spontaneous tumors (Donehower et al, 1992), dubbing it as a tumor
suppressor. The ability of p53 to execute and balance these cellular responses is crucial
in preventing tumorigenesis; bypassing these functions with damaged or broken DNA
leads to genomic instability and the beginning formation of a tumor. More specifically,
deletion of p53 does not allow for the transactivation of putative downstream targets
needed to initiate p53-mediated apoptosis or cell cycle arrest—two important arms in the
network of p53 tumor suppression.
1.3.1 p53-mediated apoptosis
Apoptotic cell death is crucial for eliminating cells that have accumulated
genomic instability and evaded cell cycle checkpoints allowing for improper and
uncontrolled proliferation. Central to this mode of death is p53, as evidenced through
the abrogation of radiation-induced apoptosis in thymocytes lacking endogenous p53
(Clarke et al, 1993; Lowe et al, 1993). Simplistically, apoptosis is triggered by two
types of stimulation—extrinsic or intrinsic; the former being initiated through external
cell surface receptors while the latter is activated by certain stresses which all converge

to the mitochondria. As mentioned above, p53 acts as a transcription factor, binding to
the p53 consensus response elements in the promoters of proapoptotic target genes such
as Bax, Puma, Noxa, and Bid (Fridman & Lowe, 2003). These Bcl-2 family members
further initiate the release of cytochrome C from the mitochondria initiating an
apoptotic-signaling cascade leading to cellular death.
1.3.2 p53 and the cell cycle
The eukaryotic cell cycle is a highly regulated succession of events responsible
for cellular replication, important for the homeostasis of many organs. Simplistically,
this cycle can be broken down into two stages: interphase, when the cell prepares for
proper self duplication, and mitosis, when one cell physically divides into two
genetically identical yet separate cells. Interphase can be further divided into the G 0
(Gap 0), G1 (Gap 1), S (synthesis), and G2 (Gap 2) phases—these phases are not
bidirectional, once a cell advances phases, there is no reversal. The transitions from G1
to S, S to G2, and G2 to M are tightly regulated and will not occur unless certain criteria
have been reached—the barriers preventing progression into different stages is termed
cell cycle checkpoints (Tavana & Zhu, 2011). The advancement through each phase is
dependent on cyclins binding their respective cyclin-dependent kinases (CDKs), which
in turn can phosphorylate downstream targets, initiating cell cycle progression. Alone,
cyclins and CDKs are catalytically inactive. Further, cell cycle regulation comes in the
form of cyclin/CDK complex inactivation and inhibition through cyclin-dependent
kinase inhibitors (CDKIs) (For recent reviews, see refs. (Besson et al, 2008; Malumbres
& Barbacid, 2009)). In general, overexpression of cyclins and CDKs or repression of

CDKIs should progress the cell cycle, while loss of cyclins and CDK expression or
elevation of CDKI levels should prematurely prevent cycling.
Genotoxic stress compromising the stability and structure of DNA activates a
damage response responsible for inhibiting cell proliferation. These genomic insults are
dangerous if not repaired because they can lead to genomic instability, gene mutations
and potentially tumorigenesis in the face of uncontrolled proliferation. The purpose of
halting the cell cycle, creating a checkpoint, is to allow time for DNA repair factors to
fix the damage. To prevent future complications, like chromosomal instability and
tumor formation upon excessive or irreparable damage, the cell will initiate different
terminal cellular responses—programmed cell death, termed apoptosis, or permanent
cell cycle arrest, termed cellular senescence (Negrini et al, 2010). More specifically,
cellular senescence is the process of irreversible cell-cycle arrest, halting the
proliferation of damaged cells despite mitogenic signals. Telomere erosion, oncogenic
stress, and DNA damage can all activate cellular senescence through different pathways,
but similarly converge upon activation of the DNA damage response (DDR). This
signal amplification cascade initiates the expression of key tumor suppressors which
play an important role in the induction/maintenance of cellular senescence (Campisi,
2005). Although senescent cells undergo phenotypic changes in morphology, including
hypertrophy and flattening/enlargement of cells, the most common and reliable method
for detection and differentiation from a quiescence state (a temporary arrest of the cell
cycle) is the expression of senescence-associated -galactosidase (SA-gal) (Dimri et al,
1995) (for a current protocol for detection of SA-gal, see ref. (Debacq-Chainiaux et al,
2009). By permanently halting the proliferation of cells with unrepaired damage or

Telomere
shortening

Chemical
exposure

DSBs
(γ-IR)

Oncogenic
stress

Cellular
Metabolism

DNA Damage

DDR

p53

DNA Repair

Apoptosis

Transient Cell
cycle arrest

Senescence

Autophagy

Figure 2. The p53 activation and signaling network.
Many different stress stimuli induce DNA damage and activate the DNA damage
response (DDR), including telomere shortening, chemical exposure, DNA double
strand breaks (DSBs), oncogenic stress and cellular metabolism. The DDR activates
p53 to induce putative downstream targets, initiating DNA repair, transient cell cycle
arrest, autophagy, apoptosis and cellular senescence. Bolded, are the responses
known as barriers against tumorigenesis.

genomic instability, senescence acts in parallel to apoptosis by suppressing
tumorigenesis (d'Adda di Fagagna, 2008). While this mechanism is beneficial for cancer
prevention, increases in senescent cells can also be deleterious to tissue homeostasis and
cell renewal, leading to premature aging and ageing-related disorders.
1.3.3 Cellular Senescence
The process of irreversible cell-cycle arrest, halting the proliferation of damaged
cells despite stimulations with mitogenic factors is termed cellular senescence. Upon
DNA damage, cells will initiate an amplification signal cascade, DNA damage response
(DDR), activating key tumor suppressor pathways, either p53 or pRB, which play
important roles in the induction of cellular senescence (Campisi, 2005).

In fact,

constitutive activation of the DNA damage response pathway, independent of actual
DNA damage, is sufficient to induce cell cycle arrest and cellular senescence (Toledo et
al, 2008). Although senescent cells permanently have arrested cycling, they remain
metabolically active. Recently, much work has focused on identifying different secreted
factors senescent cells expel which affect neighboring cells and the tumor
microenvironment—senescence associated secretory phenotype (SASP). Of interest,
IL6, IL8, and their respective receptors have been associated with the induction and
maintenance of DNA damage/p53 mediated cellular senescence (Acosta et al, 2008;
Kuilman et al, 2008; Rodier et al, 2009). Collectively, these articles reveal that the
context-specific secretion of IL6 and IL8 lead to cellular arrest signals and created a
positive feedback loop connecting the DDR to the propagation and maintenance of
cellular senescence. These soluble factors have been proposed to play a significant role
during tumor suppression by inducing senescence in neighboring cell types halting their

secretion patterns as well as initiating a pro-inflammatory response to initiate the
removal of senescent cells (Kuilman & Peeper, 2009; Xue et al, 2007). In this context,
senescence plays a parallel role to apoptosis in eliminating tumorigenic cells.
1.3.4 CDK inhibitor p21 and mutant p53p/p
The putative downstream target of p53 playing a critical role in cell cycle
checkpoint regulation and cell proliferation is p21, which inhibits the kinase activity of
CDKs and prevents the cell from entering the S phase (Abbas & Dutta, 2009; Harper et
al, 1993). As evidence that p21 plays a pivotal role in p53 mediated cellular senescence,
its deletion led to the bypass of senescence and permitted replication after DNA
damage(Brown et al, 1997). In fact, in the hypomorphic mutant p53R172P background,
where p53 retains cell cycle checkpoint function but not apoptosis (hereafter referred to
as p53p/p) (Liu et al, 2004), p21 suppresses genomic instability; deletion of p21 led to
loss of cell cycle control and accelerated tumorigenesis (Barboza et al, 2006).
Additionally, p21 is elevated upon DNA damage due to nonhomologous end joining
(NHEJ) deficiency, which led to tumor suppression in the p53p/p background (Van
Nguyen et al, 2007). The loss of cell cycle checkpoint control is pivotal in allowing
normal cells to transform into cancer cells. These studies highlight the importance of
p21 and indicate a potential therapeutic target in cancer cells upon p53 loss.

1.4

Diabetes Overview
One of the most prevalent worldwide metabolic disorders is type 2 diabetes,

often resulting from defects in maintaining sufficient numbers of insulin-secreting cells. This unique subset of endocrine cells controls glucose homeostasis in response to

the body’s metabolic demands. Although proliferation occurs at an extremely slow rate,
maintenance of -cell number and islet mass is critical to sustain normoglycemia (Dor et
al, 2004; Georgia & Bhushan, 2004). In fact, the production of these insulin-producing
-cells in adults does not occur through differentiation of their stem-cell progenitors but
predominantly through self-duplication of mature cells (Dor et al, 2004; Georgia &
Bhushan, 2004; Salpeter et al, 2010; Teta et al, 2007).

However, the principle

mechanism during embryogenesis remains as neogenesis, when precursor cells give rise
to new -cells. -cell replication and subsequent islet mass expansion are regulated not
only by extrinsic growth factors, but also in response to physiological demands
(Ackermann & Gannon, 2007). Consequently, disrupting the self-replicating capability
of -cells leads to a decrease in islet mass, reducing the production of insulin. This in
turn, deregulates glucose homeostasis, and ultimately, drives hyperglycemia leading to
overt diabetes.

Therefore analyzing the pathways that control islet mass and

understanding the mechanisms that regulate -cell regeneration will allow for novel
therapeutic interventions for the prevention or treatment of diabetic patients (Tavana &
Zhu, 2011). One strategy is to coax -cells into continued proliferation without causing
hyperplasia leading to insulinomas and hypoglycemia. To do this, we need a better
understanding of the regulation during -cell replication. It is currently well established
that the regulation of -cell proliferation and regeneration is controlled through cell
cycle proteins and more recently, their upstream modulators.

Additionally, recent

reports have focused on DNA damage and the respective activated cellular response,
which permanently halts the cell cycle of -cells leading to diabetes.

Ultimately,

regardless of the stimuli used to foster -cell regeneration, they must all converge on the

basic cell cycle replicative machinery. Many recent studies have focused on the cell
cycle regulation of pancreatic -cells, leading to disrupted glucose homeostasis and
pathologically linking cellular senescence to Type 2 Diabetes Mellitus (Tavana & Zhu,
2011).
1.4.1 The role of Cyclins
Cyclins are named by their oscillating pattern in production and destruction
during specific phases of the cell cycle; specifically, they regulate their partner cyclin
dependent kinases, through protein-protein interactions, progressing the cell cycle
(Malumbres & Barbacid, 2009). For example, the transition from G1 to S phase in the
murine islet is initiated by D-type cyclins, which bind and activate CDK4. Upon
activation, retinoblastoma is hyperphosphorylated, relieving the inhibition of
transcription factor E2F, whose targets are involved in DNA replication during S phase.
Transcription of cyclin E is also initiated, allowing for binding to CDK2, pushing the
cell into S phase (Malumbres & Barbacid, 2009).
In the murine islet, loss of specific cyclins or CDKs leads to cell cycle arrest,
which under some stress- and cell-specific conditions can lead to cellular senescence
(Campaner et al, 2010; Georgia & Bhushan, 2004; Kushner et al, 2005; Rane et al, 1999;
Tsutsui et al, 1999) while aberrant expression of these proteins leads to increased
proliferation and hyperplasia (Cozar-Castellano et al, 2004; He et al, 2009; Rane et al,
1999; Zhang et al, 2005) (Table 1). There are three D-type cyclins (D1, D2, D3), which
bind to and activate CDK4 in the murine islet, promoting cell cycle progression. Cyclin
D1 and D2 are expressed in islets, the latter in higher abundance (Cozar-Castellano et al,
2006c; Fatrai et al, 2006; Georgia & Bhushan, 2004; Kushner et al, 2005). As β-cell

replication decreases with age, so do the expression levels of cyclin D1 and D2 (Hinault
et al, 2008). Cyclin D2, although not required for neonatal development, is critical for
regulating β-cell growth and replication (Georgia & Bhushan, 2004; Kushner et al, 2005).
Genetic ablation of cyclin D2 led to stark decreases in islet mass, attenuated β-cell
proliferation rates, and glucose intolerance, eventually resulting in diabetes (independent
of apoptosis) (Georgia & Bhushan, 2004; Kushner et al, 2005). Cyclin D1 partially
compensates in the absence of cyclin D2, since the double mutant exacerbates this
phenotype with uncontrollable diabetes driving death at an early age (Kushner et al,
2005). These studies indicate that D-type cyclins can control β-cell replication and mass,
ultimately regulating glucose homeostasis (Tavana & Zhu, 2011). Mice expressing a
single point mutation at site 280 of cyclin D2 (Cyclin D2T280A), causing its constitutive
activation and stabilization, present with a massive expansion of β-cells and improved
glucose tolerance upon age. Interestingly, this was not caused by an increase in β-cell
proliferation, rather β-cell turnover decreased at an early age, contributing to the
accumulation of β-cells and increased islet mass over time (He et al, 2009). Many
human endocrine tumors have increased levels of cyclin D1 (Chung et al, 2000).
Researchers overexpressed cyclin D1 in the murine islet in vivo and found a drastic
increase in islet mass without changes in apoptosis, suggesting β-cell replication as the
culprit of the islet hyperplasia (Zhang et al, 2005). Excitingly, the β-cell specific
overexpression of cyclin D1 did not lead to hypoglycemia; in fact glucose and insulin
levels remained similar to wild-type (Zhang et al, 2005) suggesting a potential role for
targeting cyclin D1 to increase β-cell proliferation. Collectively, these studies provide
direct evidence that deletion of cyclin D molecules from the murine islet halts the cell

cycle, decreasing β-cell proliferation rates, while overexpressing cyclin Ds in β-cells
lead to increased proliferation from overactive cell cycle progression (Tavana & Zhu,
2011).
1.4.2 The role of Cyclin dependent kinases
Both CDK2 and CDK4 are expressed in murine islets, with no significant change
of CDK4 upon age, while CDK6 has not been detected (Cozar-Castellano et al, 2006a;
Hinault et al, 2008; Martin et al, 2003). Presumably due to the lack of compensation
from CDK6 expression in the islets (Cozar-Castellano et al, 2006c; Martin et al, 2003),
the phenotype of CDK4 knockout mice presents a smaller body size with the testis,
ovary, and pancreas showing replication defects (Rane et al, 1999; Tsutsui et al, 1999).
Interestingly, mutant mice developed overt diabetes due to stark decreases in insulin
production. This was attributed to the drastic decrease in islet mass, independent of
apoptosis and autoimmunity, propelling the consequent dysregulation of glucose
homeostasis (Mettus & Rane, 2003; Rane et al, 1999; Tsutsui et al, 1999). Collectively,
these findings introduce CDK4 as the mainstay for postnatal β-cell proliferation (Tavana
& Zhu, 2011). Seeing that CDK4 deletion leads to diminished β-cell proliferation, it
would not be unexpected for CDK4 overexpression to increase β-cell replication. Indeed,
Andrew Stewart’s group showed that adenoviral delivery of CDK4 into human and rat βcells did increase β-cell proliferation rates, which was elevated further with concomitant
cyclin D1 infection (Cozar-Castellano et al, 2004). Interestingly, an Arg to Cys point
mutation at amino acid 24 in the CDK4 protein (CDK4R24C), initially identified from
melanoma patients, renders CDK4 insensitive to p16 inhibition, becoming constitutively
active (Wolfel et al, 1995; Zuo et al, 1996). A knock-in mouse was created and found to

have profound β-cell proliferation rates and islet hyperplasia (Rane et al, 1999).
Confirming these results, a CDK4R24C β-cell specific knock-in was created (under the
control of the insulin promoter) with similar results as above, although insulinomas were
not observed. Taken together, these works indicate that regulation of CDK4 is central to
the maintenance of β-cell replication (Tavana & Zhu, 2011).
1.4.3 The role of Cyclin Dependent Kinase Inhibitors
The inhibitors of active cyclin/CDK complexes make up two families: the
INK4/ARF family composed of p16INK4a, p15INK4b, p18INK4c, and p19INK4d and the
CIP/KIP family composed of p21Cip1, p27Kip1, and p57Kip2. INK4 family members bind
to both CDK4 and CDK6 blocking consequent activation by inhibiting D-type cyclin
binding, while CIP family members bind both cyclins and CDKs (cyclin-D, -E, and -A
and their respective CDKs) (Besson et al, 2008).
Persistent elevation of CDKI expression in murine islets either by negative
regulation of upstream epigenetic modulators or ectopic expression leads to cell cycle
arrest and in some conditions cellular senescence (Chen et al, 2009; Dhawan et al, 2009;
Uchida et al, 2005; Yang et al, 2009; Zhong et al, 2007), while combinatorial deletion of
CDKIs (due to overlapping compensation) or deletion of positive epigenetic regulators
modulating CDKI loci lead to islet expansion and hyperplasia (Bertolino et al, 2003;
Crabtree et al, 2003; Franklin et al, 2000; Georgia & Bhushan, 2006; Karnik et al, 2007;
Karnik et al, 2005; Rachdi et al, 2006; Uchida et al, 2005) (Table 1).
1.4.3a p27 and epigenetic regulation
β-cells adapt to metabolic needs by rapidly increasing β-cell proliferation,
leading to an expansion and rise in numbers (Georgia & Bhushan, 2004). Analysis of

CDKI’s in terminally differentiated β-cells revealed marked increases in p27 levels.
Deletion of p27 leads to a burst of β-cell proliferation and islet mass at early postnatal
time periods, implicating its role in maintaining a transient cell cycle arrest, or state of
quiescence in these cells (Georgia & Bhushan, 2006). p27 deficient mice showed
improved glucose tolerance and increased insulin secretion (Rachdi et al, 2006).
Interestingly, adult mice did not show islet hyperplasia, indicating some overlapping
parallel CDKI functions to regulate β-cell proliferation (Georgia & Bhushan, 2006).
Knocking out p27 in previously established diabetic models (Irs2-/- and Lepr-/-) rescued
the β-cell proliferation defects, pointing to therapeutic targeting of p27 (Uchida et al,
2005).

Conversely, specifically overexpressing p27 in the murine islet (Rip-CDKn1b)

resulted in a severe decrease in β-cell proliferation and smaller islet mass driving
hyperglycemia and overt diabetes (Uchida et al, 2005). Collectively, these experiments,
along with additional postmortem human diabetic sample analysis (which also showed
increased nuclear p27 (Uchida et al, 2005)), emphasizes the notion that p27 is a key
regulator during conditions that require increases in β-cell mass. Therefore negative
targeting of this CDKI may be an important therapeutic strategy for facilitating β-cell
regeneration (Tavana & Zhu, 2011).
Since p27 prevents the activation of cyclin E/CDK2 and/or cyclin D/CDK4
complex formation, regulation of its turnover becomes critical to allow transitioning
between cell cycle phases. The E3 ubiquitin ligase SKP2 (S-phase kinase-associated
protein 2), which is part of the SKP-CUL1-F-box complex, ubiquitinates p27 for
proteasome-mediated

degradation;

therefore

SKP2-deficiency

results

in

the

accumulation of p27 levels. Similar to the RIP-p27 transgenic mouse (Uchida et al,

2005), this increased level of p27 leads to a decrease in β-cell mass and diabetes, which
is rescued upon p27 deletion (Zhong et al, 2007).
Positive regulation by transcriptional promotion of p27 and other CDKI’s (such
as p18) is a function of the tumor suppressor multiple endocrine neoplasia type 1 (Men1)
encoded by the gene menin. Men1 regulates gene transcription by functioning in a
histone methyltransferase protein complex, promoting the transcription of different
genes (similar to Bmi-1 and Ezh2 discussed below) (Karnik et al, 2005). Patients with
mutations in MENIN develop multiple tumor types including pancreatic islet tumors.
Since the Men1-/- mutation presents embryonic lethality, heterozygous (Crabtree et al,
2001) and conditional RIP-Men1 mice were created (Bertolino et al, 2003; Crabtree et al,
2003). Both models were characterized with severe pancreatic islet hyperplasia due to a
massive increase in β-cell proliferation. Complete β-cell analysis of Men1+/- mice by
Seung Kim’s group linked the islet hyperplasia phenotype to concomitant
downregulation of p27 and p18 (Karnik et al, 2007; Karnik et al, 2005). Conversely,
Menin overexpression led to impaired cellular proliferation and growth (Karnik et al,
2005), which could be explained by the activation of chromosome modifications
inducing premature cellular senescence (as seen with Bmi-1 and Ezh2 mutants) (Shin et
al, 2010). Collectively, these studies all highlight the importance of p27 as a modulator
of β-cell mass and islet homeostasis and present new therapeutic targets not only to
repress p27 and other CDKI’s in concert, but also to modulate their upstream regulators
to increase islet mass without inducing insulinomas (Tavana & Zhu, 2011).

Table 1: β-cell replication models in vivo.
Category

Mouse Model

Whole body/
conditional

-cell
proliferation

Islet
mass

-cell
apoptosis

Glucose
tolerance

Diabetic

Other notes

Cyclin

Cyclin D2-/-

Whole body





NC

Intolerant

Yes

Onset: 3m and 912m

Whole body





NC

Yes

Whole body

ND ()

ND ()

ND

Cyclin D2
Cyclin D1 Tg

-cells
-cells

NC






NC

Intolerant
ND
(intolerant)
Improved
Normal

CDK4-/-

Whole body





NC

Intolerant

Yes

CDK4R24C

Whole body





NC

ND

No

Islet tumors
Rescues diabetes
by increasing
proliferation

Cyclin D1+/- D2-/-/-

Cyclin D2 D3

+/-

T280A

CDK

CDKi

Yes
No
No

p27

Whole body





ND

Improved

No

p27 Tg

-cells





NC

Intolerant

Yes

p16-/-

Whole body



ND

ND

Normal

No

p16 Tg

Whole body



ND

ND

ND

No

p21-/-

Whole body

NC

NC

NC

Intolerant

No

p21 Tg

Islet specific







ND in older
mice

Yes

-/-

die at 4m
similar to Cyclin
D2-/Islet tumors
No islet tumors

No islet
hyperplasia
similar to aged
mice
Lower insulin
levels

Refs
(Georgia & Bhushan,
2004; Kushner et al,
2005)
(Kushner et al, 2005)
(Kushner et al, 2005)
(He et al, 2009)
(Zhang et al, 2005)
(Rane et al, 1999;
Tsutsui et al, 1999)
(Rane et al, 1999)
(Georgia & Bhushan,
2006; Rachdi et al,
2006; Uchida et al,
2005)
(Georgia & Bhushan,
2006; Rachdi et al,
2006; Uchida et al,
2005)
(Krishnamurthy et al,
2006)
(Krishnamurthy et al,
2006)
(Cozar-Castellano et
al, 2006b)
(Yang et al, 2009)

Category

Mouse Model

Whole body/
conditional

-cell
proliferation

Islet
mass

-cell
apoptosis

Glucose
tolerance

Diabetic

Other notes

Refs

CDKi
modulators

SKP2-/-

Whole body





ND

Intolerant

Yes

p27

(Zhong et al, 2007)

Men1-/-

-cells





NC

ND

No

(Bertolino et al, 2003;
Crabtree et al, 2003)

Bmi-1-/-

Whole body





ND

Intolerant

Yes

Ezh2-/p38Af/+
Wip1-/Ubc-Wip1

-cells
Whole body
Whole body
Whole body







ND
ND
ND

ND
ND
ND
ND

Intolerant
Normal
Intolerant
Normal

Yes
No
Yes
No

 p27 and p18;
islet hyperplasia
p16/p19; islet
senescence
p16/p19
p16/p15/p19/p21
p16/p19
p16/p19

Terc-/- G4

Whole body





ND

Intolerant

Pre-

Lig4-/-p53P/P

Whole body





NC

Intolerant

Yes

p53/p21; islet
senescence

(Tavana et al, 2010c)

PTTG-/-

Whole body





Initial 

Intolerant

Yes

p21; islet
senescence

(Chesnokova et al,
2009; Wang et al,
2003)

ATM-/-

Whole body

ND

ND

ND

Intolerant

Yes

p53-/-

Whole body

ND

ND

ND

Normal

No

p53S18A

Whole body

ND

ND



Intolerant

Pre-

Δ40p53

Whole body





NC

Intolerant

Yes

Damage

(Dhawan et al, 2009)
(Chen et al, 2009)
(Wong et al, 2009)
(Wong et al, 2009)
(Wong et al, 2009)
(Kuhlow et al, 2010;
Minamino et al, 2009)

Increased ATM
improves glucose
tolerance
No change with
HFD
Increased ROS;
intolerance
improved with
NAC
p53
stabilization/p21

(Miles et al, 2007;
Schneider et al, 2006)
(Razani et al, 2010)

(Armata et al, 2010)

(Hinault et al, 2011)

Key for Table 1: , decrease; , increase; ND, not described; NC, no change; Pre-,
glucose intolerance but not diabetic; red font: hyperplastic models; black font:
hypoplastic models; T, threonine; A, alanine; Tg, transgenic; CDK, cyclin dependent
kinase; Sei, sertad; R, arginine; C, cysteine; ER, oestrogen receptor; TAM, tamoxifen;
pIns, insulin promoter; Rip, rat insulin promoter; CDKI, cyclin dependent kinase
inhibitor; SKP2, S-phase kinase-associated protein 2; Men1, multiple endocrine
neoplasia type 1; Ezh-2, enhancer of zeste homology 2; AF, alanine phenylalanine
substitutions; Ubc, ubiquitin C; Terc, RNA component of telomerase; G4, generation 4;
Lig4, DNA ligase IV; P, proline; S, Serine; PTTG, pituitary tumor transforming gene;
ATM, ataxia telangiectasia mutated; HFD, high fat diet; ROS, reactive oxygen species;
NAC, N-Acetyl cysteine.

1.4.3b p21
While p21 levels are detected in pancreatic -cells (Cozar-Castellano et al,
2006b; Cozar-Castellano et al, 2006c), islets can function normally when p21 is deleted.
This suggests that other cell cycle regulators may compensate to function when p21 is
deleted (Cozar-Castellano et al, 2006b). Upon potent mitogen overexpression using
hepatocyte growth factor (HGF) or placental lacogene (PL), Andrew Stewart’s group
found a specific upregulation of p21 in vitro.(Cozar-Castellano et al, 2006c) However,
in vivo, when analyzing p21 deficient mice crossed with RIP-PL mice, there were no
observable differences compared to p21+/+ RIP-PL mice,(Cozar-Castellano et al, 2006b)
suggesting the dispensability of p21 during mitogenic stimulation, exposing an overall
complexity for the role of p21 in -cells. Prior to the finding that oxidative damage
increases p21 levels (Minamino et al, 2009), researchers showed that increases in p21
are associated with the suppression of insulin expression and diabetes in Zucker diabetic
fatty (ZDF) rats (Kaneto et al, 1999). Similar phenomena have been observed, that upon
genomic damage, p21 is specifically elevated in diabetic mouse models(Chesnokova et
al, 2009; Minamino et al, 2009; Sone & Kagawa, 2005; Tavana et al, 2010c); when
deleting p21 in the PTTG-/- model (discussed below), hyperglycemia was delayed as
diabetes was partially rescued probably due to decreasing -cell senescence
(Chesnokova et al, 2009).
Recently, a double transgenic mouse was devised to inducibly overexpress p21 in
the islets (using the RIP-Cre mouse). Upon long-term p21 elevation, mice became
overtly diabetic, surprisingly due to increased levels of apoptosis (Yang et al, 2009).
Although p21 is predominantly thought to arrest the cell cycle, recent findings suggest

some interplay during apoptosis induction (Besson et al, 2008). Upon 70% partial
pancreatectomy, a technique used to force -cell replication, these p21 transgenic mice
showed a dramatic decrease in proliferation compared to the wild-type controls(Yang et
al, 2009), suggesting permanent cell cycle arrest or cellular senescence. Therefore, p21
is important in a stress-dependent context in the -cells (Tavana & Zhu, 2011).
1.4.3c p16, epigenetic regulation
After examining a plethora of organs for cell cycle marker expression change in
young and aging individuals, p16 emerged as a potential marker for aging, and a
controller for balancing tissue renewal. Of particular interest is the discovery that aging
murine islets accumulate p16 (Krishnamurthy et al, 2004). Norman Sharpless’s group
confirmed this notion through mouse models of p16 deletion and overexpression
(Krishnamurthy et al, 2006). They found that whole genome deletion of p16 rescued the
age-dependent decrease in islet proliferation rates, restoring the levels to that of younger
individuals. To further confirm that p16 drives the age-dependent decline of β-cells,
they created a mouse with an extra copy of p16. Indeed, the proliferation rate of these
younger mutant mice correlated to that of aged mice, yet these mice did not develop
diabetes nor demonstrate any metabolic defects. Additionally, p16 deletion did not
develop islet neoplasia (Krishnamurthy et al, 2006), indicating possible compensation by
other CDKI’s and/or highlighting the importance of other islet regulators (Tavana & Zhu,
2011).
One mechanism that controls p16 regulation occurs at the transcriptional level
through epigenetic changes on the INK/ARF locus, which is initiated through polycomb
group proteins. One member of this protein family is Bmi-1, a negative regulator of p16

and p19. Intuitively, Anil Bhushan’s group linked these findings to islet homeostasis.
By knocking out Bmi-1, which was found highly expressed early in life, decreasing with
age (and negatively correlating with p16), these mice express high p16 and p19 levels
correlating with decreased islet proliferation (Dhawan et al, 2009). Unlike the mouse
overexpressing p16 (Krishnamurthy et al, 2006), Bmi-1 deficiency reduced β-cell mass,
driving glucose intolerance due to premature senescence, which drastically limited the
expansion of β-cells (Dhawan et al, 2009). Another member of the polycomb family is
the histone methyltransferase enhancer of zeste homology 2, Ezh2. The conditional
Ezh2-/- mouse is basically a phenocopy of Bmi-1-/-, developing glucose intolerance and
diabetes due to decreased β-cell mass and proliferation over time (Chen et al, 2009).
Interestingly, Chen et al showed increased H3K4 tri-methylation (correlating with active
transcription) on aged β-cell DNA specifically at the p16/p19 locus and not on other
CDKI loci (p15, p21, or p27) (Chen et al, 2009). This explains why other CDKI’s are
not highly expressed with age. Ezh2-/-p16-/- double deficient mice rescued the diabetic
phenotype, further highlighting the importance/dominance of p16 in β-cell biology
(Chen et al, 2009).
Upstream of the aforementioned epigenetic modulators that regulate the p16/p19
locus lies the mitogen-activated protein kinase p38, which can negatively regulate Bmi1
through phosphorylation. Activation of p38 in certain cell lines leads to the upregulation
of p16 and p19 (Bulavin et al, 2004). After investigation of aged islets, Wong et al.
found increased levels of p38 as compared to young islets (Wong et al, 2009). Upon
introduction of a dominant negative form of p38 abrogating its total function (since p38 /-

presents embryonic lethality), all CDKI expression decreased with age in this mutant,

emphasizing the importance of p38 in CDKI regulation (Wong et al, 2009). The Wip1
phosphatase, considered an oncoprotein, is a negative regulator of p38 and decreases
with age in islets (correlating with the concomitant increase of p38 and p16/p19).
Deleting Wip1 results in p38 overexpression; with age, these mice become diabetic
(which was reversed when crossed with the p38 mutant) due to a drastic decrease in βcell proliferation and mass.

Conversely, mild overexpression of Wip1 leads to a

decrease in p16/p19 expression by decreasing p38 activity (Wong et al, 2009). These
studies collectively emphasize the importance of p16 and upstream modulators in
regulating the age-dependent decline of β-cells (Tavana & Zhu, 2011). Furthermore,
analysis of islets from wild-type 12 month old mice fed a high fat diet showed glucose
intolerance, decreased β-cell mass and plasma insulin levels, due to a lowered β-cell
proliferation and islet senescence, which was associated with an increase in activated
p38 (Sone & Kagawa, 2005), corroborating the previously mentioned findings. Taken
together with the above studies, one can infer that the stress from the high fat diet and
age activated p38, which in turn upregulates p16/p19, blocks β-cell proliferation and
activates cellular senescence leading to a decrease in β-cell mass, resulting in glucose
intolerance and onset of diabetes (Tavana & Zhu, 2011).
1.4.3d Aging
Recent back-to-back studies evaluated the ability of pancreatic β-cell
proliferation with age (Rankin & Kushner, 2009; Tschen et al, 2009). Both groups
coaxed β-cells to regenerate using multiple methods including a high fat diet, Exendin-4,
STZ treatment, and partial pancreatectomy. They found that β-cells from older mice do
not have the same capability to regenerate after damage as younger mice. Furthermore,

Bhushan’s group correlated this trend with p16 regulation: older mice had higher levels
of p16 and lower levels of Bmi-1 (Tschen et al, 2009). The plasticity of younger β-cells
allows for adaptation to changes in metabolic demand as well as different types of
damages, while aged islets are restricted in replication after such damages. This is in
part due to the changes with age in the regulation of cell cycle components, negative
regulators, as well as their upstream modulators.

Indeed, Kushner’s group took a

genomic approach to study the global changes between young and old islets (Rankin &
Kushner, 2010). They show that aged islets have different gene expression patterns in
transcription factor expression, cell cycle regulation, and chromatin remodeling among
other factors than young islets (Rankin & Kushner, 2010). These works collectively
place aging as an additional limiting factor for adaptive β-cell replication. Interestingly,
cellular senescence has been linked to some age-related diseases as well as accelerating
the onset of other diseases, therefore it may be likely that β-cell senescence, a process
involving chromatin reorganization, may play a larger role in β-cell homeostasis and
age-related regeneration of β-cells than originally thought (Tavana & Zhu, 2011).
1.4.4 The role of DNA damage and downstream activated targets
Genotoxic stresses activate the DNA damage response cascade to upregulate the
tumor suppressor p53 and putative downstream targets, halting the cell cycle, which
allows for transient DNA repair or induction of apoptosis/cellular senescence when the
damage is too extensive (Campisi, 2005; d'Adda di Fagagna, 2008). More recently,
these stresses have been shown to cause progressive β-cell dysfunction and islet specific
cellular senescence driving the onset of diabetes (Chesnokova et al, 2009; Dhawan et al,
2009; Halvorsen et al, 2000; Krishnamurthy et al, 2006; Kuhlow et al, 2010; Minamino

et al, 2009; Sone & Kagawa, 2005; Tavana et al, 2010c; Testa & Ceriello, 2007) (Table
1).
1.4.4a Telomeres
Briefly, regions of tandem repeating DNA segments that protect the ends of
chromosomes from being recognized as DNA double strand breaks (DSBs) are termed
telomeres. During each round of the cell cycle, telomeres lose these repeats, shortening
in length. Upon reaching a certain threshold, short unprotected telomeres are perceived
as DSBs (leading to genomic instability) and induce the DDR, which activates a p53mediated checkpoint that can either induce apoptosis or p21-dependent cellular
senescence (d'Adda di Fagagna, 2008; Herbig & Sedivy, 2006). To accelerate telomere
shortening and mimic premature aging, either the reverse-transcriptase portion of
telomerase (Tert) or the RNA component of telomerase (Terc), the enzyme responsible
for adding repetitive regions to the ends of chromosomes, can be deleted (Blasco et al,
1997; Lee et al, 1998).

Successive back crossing of these mutant mice leads to

shortened telomeres above the threshold for detection, activating the DNA damage
cascade and replicative senescence. Upon analysis, generation 4 (G4) Terc deficient
mice present impaired glucose clearing and impaired insulin secretion after glucose
stimulation and defective gluconeogenesis (Kuhlow et al, 2010; Minamino et al, 2009;
Sahin et al, 2011), which was partially alleviated by deleting p53 (Sahin et al, 2011).
Furthermore, islet mass was significantly decreased in G4 mice from a lack in β-cell
proliferation all due to shortened telomeres in the islets (Kuhlow et al, 2010). Increasing
stress through a high fat diet, Minamino et al. elegantly showed G4 Terc-/- mice develop
more prominent insulin resistance and glucose intolerance than age-matched wild-type

mice on a similar diet (Minamino et al, 2009). Although islets were not examined, DNA
damage, p53 activation and cellular senescence in the fat pads of these mice were
correlated with the insulin resistance.

It is tempting to speculate these islets with

shortened telomere length are undergoing cellular senescence, causing the diabetic
phenotype since it is well accepted that telomere shortening, which resembles damaged
DNA, activates p53-dependent cellular senescence (Tavana & Zhu, 2011).
1.4.4b DNA damage
Cells bearing unprotected or shortened telomeres (beyond a certain threshold) are
genomically unstable, mimicking DSBs that initiate the DDR. Considering telomere
dysfunction activates cellular senescence and insulin resistance, it is not inconceivable
that islet-specific DSBs can also initiate cellular senescence and disruption of glucose
homeostasis (Tavana & Zhu, 2011).

In fact, our research team was the first to

demonstrate this concept (described in below chapters). Utilizing a deficiency in the
non-homologous end joining pathway, the major mammalian DNA repair pathway that
fixes DSBs (Mahaney et al, 2009), combined with the absence of p53-mediated
apoptosis (Liu et al, 2004), the persistence of DNA damage led to progressive diabetes
(Tavana et al, 2010c). Specifically, the accumulation of unrepaired DNA damage,
resulting from the deletion of DNA Ligase IV activated p53 and downstream cell cycle
inhibitor p21 to initiate β-cell specific cellular senescence. Additionally, β-cell mass
progressively decreased due to diminished β-cell replication, collectively lowering
insulin levels and leading to overt diabetes. Interestingly, DNA Ligase IV levels are
considerably high in isolated wild-type pancreatic β-cells potentially protecting these
cells from excess DNA damage (Tavana et al, 2010c). Interestingly, diabetic patients

are reported to have increased levels of DNA damage coinciding with decreased DNA
repair efficiencies (Blasiak et al, 2004; LeRoith et al, 2008; Pan et al, 2007; Sliwinska et
al, 2010), highlighting the importance of not only studying the roles of the DNA damage
response and different DNA repair factors in β-cell physiology, but also increasing the
efficiency of these repair pathways during the treatment of diabetes (Tavana & Zhu,
2011). Recently, scientists reported a similar phenomenon in the islets to our model
using mice deficient for Securin, also known as pituitary tumor transforming gene
(PTTG) (Wang et al, 2003). PTTG deletion correlated with increased p53 and p21 due
to higher levels of DNA damage, activating cellular senescence in different organs
(Chesnokova & Melmed, 2010). Here, researchers show elevated p21 in -cells is
responsible for the decrease in proliferation and islet-specific cellular senescence
observed leading to the diabetic phenotype, which was partially abrogated by deleting
p21 (Chesnokova et al, 2009; Wang et al, 2003).
It is commonly hypothesized that aging occurs from an abundance of unrepaired
DNA damage which recruits the DDR to initiate the network of responses (Campisi &
Vijg, 2009). Furthermore, the increase of accumulated DNA damage and high levels of
p53 have been correlated with mitochondrial dysfunction (Sahin et al, 2011), which may
synergize with halted -cell proliferation to induce diabetes.

Consistent with this

hypothesis, these collective studies show that DNA damage (either from DNA repair
deficiencies or telomere shortening) and the downstream p53 responses directly alter the
rate of proliferation as well as the overall function on pancreatic -cells (Tavana & Zhu,
2011).
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Figure 3. Schematic of the cell cycle regulation in pancreatic β-cells.
The cell cycle regulation of β-cells is complex. Upstream cell cycle effectors can
transcriptionally regulate cell cycle kinase inhibitors. These inhibitors suppress the
activation of cyclin:CDK complexes halting the cell cycle leading to β-cell
senescence. Additionally, DNA damage can initiate cell cycle arrest protecting the
cell from genomic instability. Red font, gene deletions that directly lead to diabetes;
orange font, gene deletions that indirectly lead to diabetes; green font, gene deletions
that lead to islet hyperplasia; NHEJ, non-homologous end joining.
(Reproduced from (Tavana, 2011) with permission from Cell Cycle)

1.4.4c ATM
The master cell cycle regulator, ataxia telangiectasia mutated is centered in the
DNA damage response as a protein kinase phosphorylating many downstream targets
upon activation, including p53 and recently found to be linked to metabolic disorders.
Patients with this mutation (A-T) are predisposed to cancer, cereballar ataxia and skin
telangiectasia, while some patients exhibit deregulated glucose homeostasis and insulin
resistant diabetes, a poorly understood phenomenon (Bar et al, 1978; Blevins & Gebhart,
1996; Lavin, 2008; Schalch et al, 1970). Using aged, tumor-free ATM deficient mice,
researchers linked this deficiency to increased non-fasting glucose levels coupled with
glucose intolerance and overt diabetes (Miles et al, 2007). Apoptosis was not detected in
young mice and was not analyzed in older murine islets. An independent study used a
high fat diet to show that ATM haploinsufficiency was sufficient to drive glucose
intolerance and insulin resistance compared to wild-type littermates (Schneider et al,
2006). Interestingly, administration of Chloroquine, an antimalarial drug that activates
ATM independently of DNA damage (Bakkenist & Kastan, 2003), decreased both
fasting and random glucose levels in two established models of insulin resistance. ATM
was increased substantially in -cells upon Chloroquine treatment, driving the
restoration of glucose homeostasis (Schneider et al, 2006), which underscores a role for
ATM in the regulation of -cell maintenance (Tavana & Zhu, 2011). Furthermore,
deleting p53 did not change glucose tolerance or insulin secretion compared to wild-type
counterparts after Chloroquine administration and a high fat diet (Razani et al, 2010).
This can be explained by stimuli and stress specific responses—the ATM-p53 axis may
not be activated in the pancreas without specific stress, like excessive DNA damage.

These studies highlight an unique role for ATM in regulating glucose homeostasis
(Tavana & Zhu, 2011). It would be interesting to analyze the morphometry of islets in
aged ATM deficient diabetic mice as well as to further understand exactly what
mechanistic role ATM deficiency plays in -cells. ATM is also involved in DNA repair
and its deficiency has been linked to increased levels of DNA damage (Shiloh, 2003)
and premature senescence after genotoxic stress (Zhan et al, 2010) (similar to the NHEJ
deficiencies). Therefore, we can interpret with caution that ATM deficiency might lead
to increased levels of unrepaired DNA damage in the islets leading to the dysfunction of
β-cells and ultimately diabetes; further investigation is needed (Tavana & Zhu, 2011).
1.4.4d p53
Stress prompts ATM to stabilize and activate p53 via phosphorylation—
primarily on Serine 18 (Ser15 in humans) (Banin et al, 1998; Canman et al, 1998).
Abrogating this phosphorylation site through mutation would theoretically abolish this
ATM-p53 pathway, allowing further study of the impaired glucose homeostasis seen in
ATM deficiency. Using the p53 mutant, p53S18A, researchers indeed found metabolic
dysregulation through impaired glucose tolerance and insulin resistance (Armata et al,
2010). Furthermore, this phenomenon was ablated upon antioxidant administration,
demonstrating increased oxidative stress as the cause for this metabolic disorder.
Combined with the previous studies utilizing ATM deficiency (Miles et al, 2007), these
data highlight the importance of the ATM-p53 pathway in maintenance of glucose
homeostasis. Yet the role of p53 during glucose homeostasis is still emerging (Tavana
& Zhu, 2011). Recently, Minamino and colleagues unequivocally demonstrated a role
for cellular aging in the influence of insulin resistance and type 2 diabetes through p53

(Minamino et al, 2009). Using a previously characterized obese diabetic model resulting
from ectopic expression of the agouti peptide (Ay), they first showed that increased
levels of oxidative damage in the adipose tissue activated p53/p21-dependent cellular
senescence (independent of telomere-shortening). Decreasing p53 levels (using Ay
p53+/- mice) drastically reduced the cellular senescence and normalized the increase in
senescence-associated inflammation (associated with insulin resistance), significantly
improving overall insulin sensitivity and glucose tolerance. Conversely, overexpressing
p53 in adipose tissue led to increased p21 levels and higher circulating pro-inflammatory
cytokines associated with glucose intolerance and insulin resistance. Further, analyzing
fat pads from diabetic patients showed an increase in p53/p21, senescence, and
senescence-associated inflammation (Minamino et al, 2009). Thus, the DNA damage
from an increased caloric intake triggers activation of p53/p21 dependent senescence in
adipose tissue, altering inflammation which collectively drives insulin resistance and
diabetes (Tavana & Zhu, 2011). A proteomic study utilizing isolated human islets from
patients with type 2 diabetes showed elevated p53 expression (Nyblom et al, 2009),
while p53 has also been identified in cycling murine islets (Cozar-Castellano et al,
2006c).

Yet when comparing young and aged -cells, there was no significant

difference in the p53 expression level as detected by immunostaining (Hinault et al,
2008). Recently, Rohit Kulkarni’s group utilized a mouse model with an extra copy of
the p53 isoform that presents with p53-dependent accelerated aging (Δ40p53 (Maier et al,
2004)) (Hinault et al, 2011). These mice have increased p53 stabilization with elevated
levels of p21 and decreased cyclin D2 levels.

Furthermore, these mice exhibited

progressive diminishment of -cell proliferation and mass, which was sufficient to drive

hypoinsulinemia, glucose intolerance and age-dependent diabetes (Hinault et al, 2011).
In conjunction with the conclusions drawn from the previously mentioned work, p53 is
becoming a more attractive link between aging and diabetes (Tavana & Zhu, 2011).
1.4.5 Diabetes Summary
Loss or dysfunction of pancreatic -cells causes a progressive onset of diabetes,
due to the unique function of these cells that cannot be compensated by any other cell
type. Considering the predominant mechanism of -cell generation is through selfrenewal, it becomes essential to understand and manipulate this proliferative regulation
for therapeutic interventions. Recent findings using animal models that underscore the
complexity of cell cycle regulation and genomic damage response in the pancreatic cell are summarized in Figure 3 and Table 1. The commonality of many of these models
converge on the notion that cell cycle dysregulation will halt the proliferation of -cells,
triggering cellular senescence in some cases, decreasing islet mass and insulin levels
subsequently causing this metabolic disorder (Tavana & Zhu, 2011). To circumvent this
problem, we need to find targets relieving the proliferative restriction placed on -cells
without driving neoplasia. However, many upstream transcriptional regulators of the
cell cycle machinery that control -cell proliferation are yet to be characterized.
Additionally, the effects of genomic stresses, such as those induced by a high fat diet, as
well as the role of DNA repair and the DNA damage response still remains elusive
during the maintenance and regulation of -cell homeostasis. In certain cases, targeting
these pathways may help rescue glucose intolerance and avoid permanent cell cycle
arrest. Interestingly, diabetic patients are reported to have increased levels of DNA
damage coinciding with decreased DNA repair efficiencies (Blasiak et al, 2004; LeRoith

et al, 2008; Pan et al, 2007; Sliwinska et al, 2010), highlighting the importance of not
only studying the roles of the DNA damage response and different DNA repair factors in
β-cell physiology, but also increasing the efficiency of these repair pathways during the
treatment of diabetes (Tavana & Zhu, 2011).

1.5

Dissertation Summary
In this dissertation, we provide the first direct evidence that the accumulation of

DNA double strand breaks in the pancreatic islets, using the nonhomologous end-joining
knockout Ligase IV, activates p53 to initiate cellular senescence (in the absence of
apoptosis) and cause diabetes. This decrease in β-cell proliferation impacts glucose
homeostasis through islet attrition (Tavana et al, 2010c). This study highlights two
important features: the importance of NHEJ in mending spontaneous DNA double strand
breaks, and the respective p53-activated response. Further, to delineate upstream NHEJ
factors in the pancreatic β-cell, we utilized the Ku70-/- mouse model. Interestingly, we
identified a novel role for Ku70 independent of the NHEJ pathway, which is to somehow
modulate Wnt signaling.

The stabilization of Wnt signaling, augments β-cell

proliferation directly leading to islet propagation and increased insulin levels. This
explains the hypoglycemia observed. Lastly, we analyze the impact of single strand
breaks, using UVB radiation, in the absence of p53-mediated apoptosis (Tavana et al,
2010a).

Here we show that low doses of UVB elevate inflammation, increase

immunosuppression, and elevate skin damage in the absence of p53-mediated apoptosis
in vivo. Further, mechanistically, we show both in vivo and in vitro that without p53mediated apoptosis, in the presence of single-stranded DNA damage, cellular senescence

is initiated as a ‘fail safe’ response to prevent genomic instability. Taken in aggregate,
these studies show that both single strand DNA damage as well as double strand DNA
damage activates cellular responses that lead to aging related phenotypes—either
photoaging or diabetes. Further, our models portray the importance of initiating cellular
senescence as a mechanism to prevent tumorigenesis, although coming with a cost.

CHAPTER 2
MATERIALS AND METHODS

2.1

Generation of Mouse Models
Wild-type, p53p/p (Liu et al, 2004) and p53-/- (Donehower et al, 1992) mutant

mice were bred into a mixed C57BL/6 and 129SV background. DNA Ligase 4+/- (Frank
et al, 1998) mutant mice were crossed to p53p/p or p53-/- mice to generate Lig4-/-p53p/p
(Van Nguyen et al, 2007) and Lig4-/-p53-/- (Zhu et al, 2002) respectively. Ku70+/- (Gu et
al, 1997) mice were crossed to each other to create Ku70-/- or with p53p/p to generate
Ku70-/-p53p/p. The protocols were approved by the Institutional Animal Care and Use
Committee at The University of Texas M.D. Anderson Cancer Center.

2.2

Acute Irradiation
For acute studies, mice were shaved on the dorsal area and irradiated once at

indicated doses from a 137Cs γ-ray source (JLS Shepard & Associates, Glendale, CA), or
UV using four FS40 sunlamps (National Biological, Twinsburg, OH) (Nghiem et al,
2002; Sreevidya et al, 2010). The UVB output of the sunlamps was measured with an IL
1700 radiometer. At indicated time points post irradiation, the dorsal skin fold was
measured with calipers and skin samples from areas of irradiation were frozen in liquid
nitrogen and a portion fixed for further studies. DNA was extracted from the frozen
samples. Radioimmunoassay was performed to determine the extent of cyclopyrimidine
dimer and (6-4) photoproduct formation (Mitchell, 2006).

2.3

Immune Suppression
To measure the effect of UVB on the immune response, a delayed-type

hypersensitivity reaction was used, as described (Nghiem et al, 2002). Mice were shaved

on the dorsal side and the following day they were given indicated amounts of UVB
radiation. Five days later they were immunized with formalin-fixed Candida albicans.
Delayed-type hypersensitivity, as determined by an increase in footpad swelling in
response to a challenge with C. albicans-specific antigen (Alerchek, Portland, ME), was
measured 10 days post immunization. The mean change in footpad thickness (left foot +
right foot ÷ 2) was calculated for each animal in the group (N = 5). The change in
thickness ± the SEM was then calculated for the group.

2.4

Cell culture and UV irradiation
Murine embryonic fibroblasts ~day 13.5 were grown in Dulbecco’s modified

Eagle’s medium (Mediatech) supplemented with 10% fetal bovine serum (SAFC
Biosciences), and 100U/mL penicillin (Cambrex). Cells were plated in 10cm dishes in
an incubator at 37ºC with 5% CO2. An FS40 sunlamp was used for irradiation; UV
output was measured with an IL 1700 radiometer. Upon subconfluency, cells were
exposed to different UVB doses in a thin layer of PBS. Control cells were kept in the
same culture conditions without UVB.

2.5

Radiation Sensitivity Assay
Briefly, MEFs were seeded onto 6cm dishes and later irradiated with differing

dosages of ionizing radiation by using a 137Cs γ-ray source. After irradiation, the medium
was replaced and cultures were incubated for 7 days at 37°C with a change in media at
day 3. At the end of the assay, MEFs were trypsinized, and viable cells were counted.

Additionally, MEFs were plated onto 10cm dishes and irradiated with UVB as described
above and viability was assessed 3 days after irradiation.

2.6

Apoptosis and Cell Cycle Analysis by flow cytometry
MEFs were irradiated either with ionizing radiation or UVB as stated above and

collected at indicated time points. Apoptosis was analyzed using a FITC-Annexin V
Apoptosis detection kit (BD Pharmingen). Data were collected using a flow cytometer
(FACScalibur, Becton Dickinson) and analyzed by FlowJo software (Tree Star, OR).

2.7

Skin histology and immunofluorescence
“Skin was fixed in Bouin (Ricca Chemical Company) solution in room
temperature, overnight. Upon fixation, tissue was dehydrated by passing through
ethanol followed by xylene. and embedded in paraffin for histological analysis.
Sections (6μm) were incubated with antibodies against p53 (Cell Signaling), and
p21 (Santa Cruz). Secondary antibodies were applied according to the
manufacturer’s recommendations and incubated with Vectashield Hard Set with
DAPI (Vector). Slides were analyzed by fluorescent microscopy (Olympus
BX41). Additionally, a transferase-mediated dUTP nick-end labeling (TUNEL)
assay kit (Promega) was used to detect apoptosis with DNase-1 treated sections
as positive controls” (Tavana et al, 2010b).

2.8

Cellular senescence
Senescence-associated β-galactosidase (SA-β-gal) activity was detected in the

skin by a staining kit (Cell Signaling). SA-β-gal activity in MEFs was detected as
described (Dimri et al, 1995). Slides were subjected to hematoxylin-eosin (H&E)
staining and examined by light microscopy (Olympus BX41). MEFs positive for SA-βgal activity were scored against total cells using ImageJ (National Institutes of Health,
Bethesda, MD). For islet senescence, blocks were sectioned (6µm) and insulin was
detected by immunohistochemical staining. Slides were counterstained with Nuclear
Fast Red (Vector).

2.9

Western Blot Analysis
Cells were irradiated as stated above and collected in lysis buffer. 40μg of protein

was loaded onto a 10% polyacrylamide gel. After transfer, the PVDF membrane
(Biorad) was incubated with antibodies for p53, PUMA, and pChk1 (S345) (Cell
Signaling), p21 (BD Pharmingen), PARP and Noxa (Abcam), Cdk4, Bcl-2 and Bax
(Santa Cruz), Bak (Calbiochem), GAPDH (Epitomics), Ku70 (Abd Serotec), and βActin (Thermo Scientific). Horseradish peroxidase conjugated secondary antibodies
were applied per the manufacturers’ recommendations. Signals were detected with an
enhanced chemiluminescence kit (Perkin Elmer).

2.10

Measurement of Blood Glucose and Insulin Levels

“For the glucose tolerance test, mice were fasted for 16 hours and injected
intraperitoneally with glucose at 1.0g/kg body weight. For the insulin tolerance
test, mice were fasted for 6 hours and injected intraperitoneally with insulin at
0.75U/kg (Sigma). Glucose levels were measured using a glucose analyzer
(Bayer Contour). Blood insulin levels were measured by enzyme-linked
immunosorbent assay (ELISA)” (Tavana et al, 2010b).

2.11

Pancreatic histology, immunohistochemistry and immunofluorescence
“Pancreata were fixed in Shandon Cryomatrix (Thermo) and placed at 20°C or Bouin’s Solution (Ricca Chemical Company) overnight, dehydrated
through ethanol and embedded in paraffin for histological analysis. Blocks were
sectioned (6µm), deparaffinized, and rehydrated in decreasing concentrations of
ethanol. Slides were quenched of endogenous peroxidase, permeabilized, and
blocked with Superblock (Thermo). Slides were incubated with antibodies
against Insulin, Glucagon, Cyclin D2, TCF4, and p53 (Cell Signaling), F480
(eBioscience), Cd11b, Nk1.1, β-catenin (BD Biosciences), p53, p21, and Cdk4
(Santa Cruz), PCNA (DAKO), Ku70 (Abd Serotec), or H2AX (Abcam). BrdU
was injected intraperitoneally at 100mg/kg. After 4 hours, pancreata were
sectioned. Slides were incubated with anti-BrdU (Serotec) and anti-insulin (Cell
Signaling) antibodies and analyzed. For immunohistochemistry, HRP-conjugated
secondary antibodies were applied at manufacturers’ recommendations. DABchromogen substrate mixture was applied or combined with AEC for double
immunohistochemical detection (Vector). Slides were subjected to haematoxylin

and eosin (H&E) staining and examined by light microscopy (Olympus BX41).
For immunofluorescence, secondary antibodies were applied accordingly at
manufacturers’ recommendations. Slides were analyzed by fluorescent
microscopy” (Tavana et al, 2010b).

2.12

Analysis of pancreatic morphology
“Pancreata sections were prepared as described, insulin was detected by
immunohistochemistry, counterstained with H&E. Each section was subjected to
morphometric analysis using Image J (National Institutes of Health, Bethesda,
MD). The area of the pancreas and of each islet in the tissue were measured. Raw
data was statistical analyzed” (Tavana et al, 2010b).

2.13

Pancreatic Islet isolation
“Islets were isolated through collagenase XI (Sigma) perfusion, digested,
filtered, and hand picked to purify islets as described in (Li et al, 2009). Islets
from at least 3 mice per group were pooled together and 40μg of protein was
loaded onto 6, 10, and 12% polyacrylamide gels depending on the protein of
interest” (Tavana et al, 2010b).

2.14

TUNEL assay
A terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay

kit for immunofluorescent detection (Promega) or immunohistochemical deteciton
(Millipore ApopTag) was used to detect apoptosis.

2.15

Statistical analysis
Results are presented as the mean ± SEM. Differences were determined using a

two-tailed, unpaired Student t test with CI of 95%. A P value less than 0.05 was denoted
as statistically significant (GraphPad Prism Software, GraphPad, San Diego, CA).

CHAPTER 3
ABSENCE OF P53-DEPENDENT APOPTOSIS
LEADS TO UV RADIATION HYPERSENSITIVITY,
ENHANCED IMMUNOSUPPRESSION AND
CELLULAR SENESCENCE

3.1

Introduction
Fundamental to the initiation of many tumors is the persistence of DNA damage,

which, if inappropriately repaired, can drive oncogene activation or deactivation of
tumor suppressor genes that drive cell proliferation and/or survival even in the absence
of physiological stimuli (Felsher, 2008; Negrini et al, 2010). A carcinogen that can
directly damage DNA is ultraviolet radiation (Sancar et al, 2004; Sinha & Hader, 2002).
Excessive exposure to UVR is potentially hazardous to our health, since evidence has
linked UV radiation exposure to several conditions such as gene mutations, skin
inflammation, immune-suppression, multiple types of cancers and accelerate the onset of
aging (Halliday, 2005; Hussein, 2005; Yarosh, 2004). Upon UV radiation, p53 plays an
essential role in mediating the cellular responses (Benjamin & Ananthaswamy, 2007;
Latonen & Laiho, 2005). Previous studies revealed that in the absence of one or both
alleles of p53, mice display extreme sensitivity to tumor induction by UVB and exhibit a
drastic decrease of apoptosis in the dermis (Jiang et al, 2001; Ziegler et al, 1994). More
recent studies have underscored UVB as an inducer of p53-mediated premature cellular
senescence (Borlon et al, 2008; Chen et al, 2008) as well as p53-mediated apoptosis
(Naik et al, 2007).
Cells can rapidly activate a network of pathways in response to genomic DNA
damage. A central outcome of the DNA damage response pathway is the stabilization
and activation of the tumor suppressor p53, which arrests the cell cycle to allow for
DNA repair, apoptosis, or cellular senescence—the latter two occur when the DNA
damage is too excessive or irreparable. p53 is best characterized as a transcription factor,
which can transactivate many different genes to induce and regulate a diverse network of

cellular functions crucial in protecting the cell against genome instability as well as
maintaining the homeostasis of cell growth and differentiation (Meek, 2009; Vousden &
Prives, 2009). Initial genomic insults stabilize p53 to the nucleus where transient cell
cycle arrest can be quickly activated, allowing for the repair of damaged DNA prior to
replication. Upon excessive and irreparable damage, p53 can trigger a signaling cascade
and induce programmed cell death through transcription of pro-apoptotic genes, most
notably p53-upregulated modulator of apoptosis (PUMA) and Noxa (Roos & Kaina,
2006) as well as repress anti-apoptotic genes including Bcl-2 (Zuckerman et al, 2009).
Apoptosis is a formidable barrier protecting cells against the accumulation of genomic
instability leading to tumor formation.
Besides apoptosis, DNA damage may also induce an irreversible cell cycle arrest
termed cellular senescence (Abbas & Dutta, 2009; Cheng & Chen, 2010; Morachis et al,
2010).

A key p53 target playing an important function in cell cycle checkpoint

regulation and induction of senescence is the cyclin-dependent kinase inhibitor p21.
Upon activation, p21 induces G1 arrest after DNA damage by inhibiting the
cyclinE/CDK2 complex (Abbas & Dutta, 2009; Harper et al, 1993). Permanent cell
cycle arrest can be induced through a variety of different stimuli including oncogenic
signaling (oncogene-induced senescence), telomere shortening (replicative senescence),
or stress/DNA damage independent of the previous two signals (premature senescence)
(Campisi, 2005). Regardless of the stimuli, senescence plays a parallel function to
apoptosis to prevent genomic instability thereby inhibiting tumorigenesis (Van Nguyen
et al, 2007). The decision after DNA damage to either activate cellular senescence or
apoptosis occurs via the p53 pathway, yet the triggers remain unclear—speculations

include different stimuli and strength/persistence of the signal, as well as cell type
specific responses (Junttila & Evan, 2009).
To directly decipher between p53 functions after UVR, we took advantage of a
separation-of-function, hypomorphic p53 point mutation, R172P, losing complete p53mediated apoptosis, yet retaining partial cell cycle arrest capability (Liu et al, 2004). In
this study, we found that mutant p53 mice, hereafter referred to as p53p/p, are more
susceptible to UV-induced inflammation, immunosuppression, and skin damage when
compared to wild-type mice. At the cellular level, p53p/p mouse embryonic fibroblasts
(MEFs) display UV hypersensitivity and cannot transactivate certain pro-apoptotic genes
PUMA and Noxa. Upon UVB, these cells retain the ability to upregulate p21, which
ultimately drives the premature cellular senescence and the sensitivity phenotype
observed. Conversely, the wild-type MEFs exposed to UVB undergo apoptosis because
of the ability to induce these pro-apoptotic genes. Collectively our research indicates the
importance of p53-mediated apoptosis in vivo and further shows that in its absence,
cellular senescence is triggered as a fail-safe mechanism protecting cells against
genomic instability but comes at a cost (Tavana et al, 2010a).

3.2

Results

3.2.1 Mutant p53p/p mice are hypersensitive to UVB radiation.
The tumor suppressor p53 plays a central role in the response to UV radiation
(Latonen & Laiho, 2005). Previous studies demonstrate that p53-deficient mice exposed
to chronic UV radiation show increases in skin tumor formation (Benjamin &

Ananthaswamy, 2007). To investigate the cellular response to UV radiation (UVR),
which causes inflammation and erythema in the skin, we exposed hypomorphic p53p/p
mutant mice to UV radiation to analyze the acute cutaneous inflammatory response.
Considering the difficulty to measure erythema in mice with pigmented skin, we decided
to determine the macroscopic inflammation in skin by measuring the double-fold skin
thickness after exposure to 4.5 kJ/m2 of UVB radiation. At 24 and 48 hours post UVB
exposure, the skin fold thickness marginally increased in wild-type mice by 6% and 27%
from baseline measurements, while p53p/p mice presented an average of 27% and 74%
increase, respectively (Figure 4a). Upon a second dose of UVB exposure, measurements
taken 24 hours later showed a 33% increase from baseline in wild-type skin, while up to
a 100% increase was noted in the p53p/p mice (Figure 4a). The skin fold swelling
differences in the UVB-irradiated p53p/+ mice were statistically indistinguishable from
that observed in wild-type mice. To further investigate and visualize the inflammatory
response, acutely-irradiated dorsal skin sections were counterstained with hematoxylin
and eosin, to revealed that UVR not only increased the thickness of the epidermis, but
also the dermal layer (Figure 4b). These data indicate that p53p/p mice are hypersensitive
to UVB exposure.
3.2.2 p53p/p mice are more susceptible to UVR induced immunosuppression.
It is well appreciated that UV radiation increases the risk of skin cancer
development as well as causes systemic immune suppression (Kripke, 1980; Kripke et al,
1977). Dr. Kripke’s group further explored the severity of UV-induced DNA damage
mediated immune suppression in wild-type mice (Jiang et al, 2001; Kripke et al, 1992).
To determine whether p53p/p mice exhibit a difference in their immune status
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Figure 4. Mutant p53p/p mice are hypersensitive to UVB radiation.
(A) Mice were shaved and irradiated with 4.5kJ/m2 of UVB at 0 and 48h. Skin
swelling was determined by measuring double skin-fold thickness of the dorsal skin
at indicated time points. N=5 per group. Data are the mean ± SEM, * indicates
p<0.05.(B) Representative H&E dorsal skin sections after indicated time points.
Magnification: 20X.
(Modified and reproduced from (Tavana, 2010) with permission from Cell Cycle)

upon UV exposure, we compared the extent of UVB-induced immune suppression
among genotypes. A schematic of the delayed-type hypersensitivity assay (DTH) is
shown in Figure 5a to measure the immune status, as described previously (Nghiem et al,
2002). Briefly, mice were exposed to UVB followed by an immunization with C.
albicans 5 days later. 9 days following, a challenge to the hind footpads with Candida
antigen was administered, and swelling (in mm2) was measured 24 hours later. Results
indicate that both wild-type and p53p/p non-irradiated mice mounted an effective DTH
response (Figure 5b). Interestingly, p53p/p mice were significantly more sensitive to the
immunosuppressive effects of UV radiation at relatively low UV doses, 0.5 and 2.5
kJ/m2 (p<0.005) as compared to wild-type.

At 5 kJ/m2, which induced immune

suppression in the wild-type mice, p53p/p mice demonstrated a significant increase in
immune suppression (p<0.005). No significant difference in suppression was observed
at the highest dose (10 kJ/m2). Collectively, these results indicate that the increased
susceptibility seen in p53p/p mice upon UV-induced immune suppression is in parallel
with their hypersensitivity to UVB radiation.
3.2.3 UVR induces p53-p21 driven cellular senescence in the skin of p53R172P mice.
UVB exposure is known to induce a p53-dependent apoptotic response in wildtype mouse skin (Naik et al, 2007). To determine whether UVB can also induce
apoptosis in p53p/p mice, we performed a TUNEL assay. Apoptotic cells were detected
in wild-type samples receiving 5 and 10 kJ/m2 of UVB radiation (Figure 6) while
virtually no apoptotic cells were detected in p53p/p and non-irradiated wild-type samples.
In contrast to UVR exposure, treatment with 10 Gy of ionizing irradiation induced slight
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Magnification: 20X.
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apoptosis in wild-type skin, which was absent in p53p/p skin sections. This confirmed
the apoptosis-deficient phenotype of p53p/p previously described (Liu et al, 2004).
To confirm if UVB activated a p53 response, we used immunofluorescent
staining on skin sections to determine the expression of p53 and the downstream target,
p21. Interestingly, skin sections from UV-irradiated p53p/p mice show an increased level
of both p53 and p21 proteins, while the wild-type only modestly increased in p53 and
p21 expression levels (Figure 7). The elevation of p53/p21 axis indicates cell cycle
arrest and suggests cellular senescence. To identify whether UVB activates a permanent
cell cycle arrest in skin sections, we stained for β-galactosidase (SA-β-gal), a marker
indicative of cellular senescence, at 24 and 72 hours after UVR. As shown in Figure 8,
senescent cells were observed specifically in the hair follicles of p53p/p mice 24 hours
after 10 kJ/m2 of UVB treatment; the number of these cells increased significantly 72
hours post UVB exposure. Low levels of cellular senescence were observed in skin
sections of p53 p/+ mice, yet were absent in wild-type sections even upon exposure to
ionizing radiation (IR). These results indicate that p53p/p skin cells undergo senescence
in the absence of apoptosis as a response to UVB damage. Collectively, our results
indicate that UVB induces a p53 and p21 response in both wild-type and mutant mice,
yet the mutant skin undergoes senescence instead of apoptosis, possibly due to the high
levels of p53 and nuclear p21, correlating with cell cycle inhibition activity.
3.2.4 p53p/p MEFs are specifically hypersensitive to UVR but not to γIR.
To determine the sensitivity of p53p/p cells after UVB exposure, we generated
and exposed early passage p53p/p mouse embryonic fibroblasts (MEFs) to different doses
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Figure 7. Elevation of p53 and p21 detected in p53p/p skin after UVB exposure.
Representative immunofluorescent staining of skin sections from p53p/p and p53+/+
mice; p53 (green), p21 (red) Dapi (blue). Magnification: 40X.
(Modified and reproduced from (Tavana, 2010) with permission from Cell Cycle)
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Counter staining with H&E. Magnification: 40X.
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of UVB and evaluated the rate of cell survival when compared to wild-type and p53-/MEFs. As shown in Figure 9a, UVB treatment at doses of 50, 100, and 250J/m2 were
slightly cytotoxic in wild-type cells (approximately 75, 55 and 20 percent survival
respectively), but were not as cytotoxic to p53-/- MEFs. However, survival of p53p/p
MEFs was significantly lowered when compared to wild-type and p53-/-, with the
greatest significant difference observed at 100J/m2, which accounted for only a 27%
survival rate.

These results indicate that the hypomorphic p53p/p leads to MEF

hypersensitivity after UVB treatment. Non-irradiated p53p/p MEFs grow at a similar rate
when compared to wild-type cells (data not shown), ruling out the possibility that the
observed sensitivity in p53p/p MEFs was due to a growth disadvantage in untreated
MEFs (Barboza et al, 2006).

To determine if this hypomorphic mutation is also

important for MEF survival after IR, we exposed MEFs to different doses of treatment.
As shown in Figure 9b, p53p/p and p53-/- show a relatively similar survival pattern in
response to IR, while wild-type MEFs are more sensitive, which correlates to the p53apoptotic response. A similar trend was observed after performing a colony formation
assay with both UVR and IR, at similar doses (data not shown). Therefore, these results
indicate that the hypomorphic p53 is selectively sensitive to UVB treatment and not IR.
3.2.5 Mutant p53p/p cells are able to remove UV-induced damaged bases normally.
UV irradiation induces lesions and distortions to DNA strands either by forming
cyclobutane pyrimidine dimers (CPDs) or pyrimidine (6-4) pyrimidinone photoproduct
[(6-4) photoproducts]. This type of DNA damage initiates the nucleotide excision repair
(NER) pathway and activates cell cycle checkpoints (Nouspikel, 2009). To determine if
the hypersensitivity observed in the p53p/p MEFs results from a defect in the ability to
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repair UV-induced CPD and (6-4) photoproducts, we isolated DNA from UVB
irradiated MEFs (200J/m2) at 0, 6, 24, and 48 hours after irradiation and analyzed for
remaining CPD and (6-4) photoproducts using a radioimmunoassay (Mitchell, 2006).
The results in Figure 10a reveal that the rate of removal of both CPD and (6-4)
photoproducts in the p53p/p background is as efficient as p53p/+ and wild-type cells at 48
hours after UVR. This result suggests that the removal and repair of damaged bases per
se, is not affected by the hypomorphic p53p/p mutation.
Next we analyzed if in vivo hypersensitivity observed in p53p/p mice occurs due
to problems in repair of UV-induced CPD and (6-4) photoproducts, again by extracting
DNA samples from mouse skin at 0, 6, and 24 hours post UVB. At 5.0 kJ/m 2 of UVB, a
dose which showed significant immunosuppression and hypersensitivity, the (6-4)
photoproducts were removed rapidly in both genotypes, with only 53-67% remaining at
6 hours and 19-43% still remaining after 24 hours; no significant changes in the rate of
repair between genotypes was detected (Figure 10b). The removal of CPD was initially
marginally slower with 51-71% remaining at 6 hours and 24-48% still remaining at 24
hours, yet the rate of repair was similar regardless of the genotype (Figure 10b). Taken
in aggregate, these results indicate that the increased sensitivity of p53p/p mice by UV
carcinogenesis is not caused by defects in the repair of UV-induced DNA damage.
3.2.6 Wild-type MEFs undergo apoptosis after exposure to UV radiation.
The characteristic cellular response for wild-type MEFs upon exposure to UV
radiation is to initiate apoptosis, predominantly dependent upon p53 to mediate this
death pathway (Naik et al, 2007; Zhang et al, 2008). Considering the p53p/p mutation
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renders cells resistant to p53-dependent apoptosis (Liu et al, 2004; Rowan et al, 1996),
we hypothesized that p53p/p MEFs would act similar to p53-/- MEFs in terms of initiating
apoptosis. Therefore, to determine the extent of apoptosis in wild-type and mutant
MEFs after UVB radiation, we stained irradiated MEFs with labeled AnnexinV and
propidium iodide (PI), followed by analysis by flow cytometry (Vermes et al, 1995).
MEFs were exposed to UVB (100 and 250J/m2) and harvested 24 and 48 hours later. In
response to 250J/m2 of UVB, 20% of the wild-type MEFs underwent apoptosis after 24
hours of recovery (Figure 11a), correlating with previous reports (Peters et al, 2003).
This percentage increased from 28% to 63% when cells were allowed to recover for 48h
(Figure 11b). A typical histogram profile is shown in Figure 11c. The apoptosis
observed is clearly dependent on p53, since a low level of apoptosis (under 10%) was
detected in the p53-deficient MEFs; as hypothesized, p53p/p MEFs exhibited an almost
identical apoptotic profile to p53-/- MEF, further indicating that p53p/p background is
deficient in p53-mediated apoptosis.
3.2.7 In the absence of apoptosis, p53R172P MEFs undergo senescence after UV
exposure.
Next, we asked if the initial DNA damage caused by UVB exposure could drive
p53p/p MEFs into cellular senescence. Wild-type, p53p/p and p53-/- MEFs were treated
with UVB radiation at doses of 100 and 250J/m2, harvested 24 and 48 hours later, and
scored for positively stained cells for senescence associated β-galactosidase. As shown
in Figures 12a and 12b, both wild-type and p53-/- MEFs displayed a low percentage of
senescent cells, while a significantly higher percentage of senescent cells were detected
in p53p/p MEFs. The percentage of senescent cells exceeded 50% in p53p/p MEFs 48
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hours after 250J/m2 treatment compared to less than 20% found in wild-type p53-/- MEFs.
Interestingly, although a significantly higher level of senescent cells were present in
p53p/p MEFs after IR treatment when compared with wild-type and p53-/- MEFs, the
overall number is much lower after IR treatment (only 3-6 %), indicating that MEFs do
not rapidly undergo senescence after acute IR treatment (Figures 12c and 12d).
Representative fields of senescent p53p/p MEFs stained with SA-β-gal and counterstained with H&E are shown in Figure 12e. Further, to analyze the activation of the
p53/p21 axis, we utilized immunofluorescent staining on MEFs after 100 and 250J/m2 of
UVB. In both cases, an increase in both nuclear p53 and p21 was noted in the p53p/p
mutant, indicative of activated cellular response—namely cell cycle arrest (Figure 13a
and 13b); these results are similar to that observed in the skin staining. Taken in concert
with in vivo skin data, these results indicate that the p53p/p mutation responds to UVinduced DNA damage by progressively driving cells into senescence in a time- and
dose-dependent manner, which explains the lower expansion rate after UV treatment in
p53p/p MEFs. Collectively, these results indicate hypomorphic p53p/p is activated upon
UV-induced damage, but not gamma-irradiation, to drive cells into senescence.
3.2.8 Hypomorphic p53p/p is unable to transactivate proapoptotic genes upon
UVB.
After exposure to DNA damage, p53 is stabilized and will transactivate certain
downstream targets to induce a network of cellular programs.

To determine the

differences between wild-type and p53p/p in response to UVB irradiation, we analyzed
the protein levels of known downstream p53-dependent apoptotic and cellular senescent
markers 24, 48, and 72 hours after UVB irradiation (Figure 14a). Low levels of p53
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were detected in non-irradiated MEFs as well as in MEFs that received 100J/m2 of UVB
(data not shown). However, at 250J/m2 the level of p53 in wild-type cells initially
increased (24h), but began to decrease 48 and 72h post irradiation. In contrast, p53p/p
levels constantly remained high. Increased p21 levels were noted in both wild-type and
p53p/p MEFs after UVR at 250J/m2 (Figure 14a). There is a slightly reduced level of p21
in the mutant MEFs compared to wild-type samples, which is consistent with previous
reports that p53p/p mutant cells retain a partial ability to transactivate p21 (Barboza et al,
2006; Liu et al, 2004).

Significantly, UVR upregulated the levels of proapoptotic

protein PUMA (p53 upregulated modulator of apoptosis) in wild-type MEFs, while
PUMA levels, as well as another p53-dependent proapoptotic protein NOXA, remained
low in p53p/p cells. These results are consistent with the hypomorphic mutant being
unable to transactivate p53-mediated apoptosis. Therefore, the lack of apoptosis after
UVB seen in p53p/p is partially due to the inability of mutant p53 to transactivate
proapoptotic factors that are important to induce apoptosis.

Further, anti-apoptotic

protein Bcl-2 levels decreased in wild-type after UVB treatment, which is in opposition
to that seen in p53p/p MEFs where Bcl-2 levels remained high, and only slightly
decreased at 72h in p53p/p. Lastly, the kinetics of these proteins show an activation of
PUMA, Noxa, and cleaved Parp upon 12 hours post UVB exposure in wild-type MEFs
(Figure 14b). The involvement of additional apoptotic markers, Bax and Bak, were
ruled out since these levels are not changed before or after the UVB treatment (Tavana et
al, 2010a).
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3.3

Discussion
By guarding the genome, p53 plays a central role in mediating cellular responses

after UV radiation (Latonen & Laiho, 2005; Lavin & Gueven, 2006).

This study

demonstrates that the hypomorphic p53p/p mutation leads to UVB hypersensitivity both
in vitro and in vivo. Abrogating p53-dependent apoptosis, mutant mice showed less
tolerance to UVB radiation. Upon low doses, p53p/p mice suffered from severe skin
swelling and higher immunosuppression compared to wild-type mice. However, this
was independent to changes in repairing the UV-induced damage, indicating that the
increased susceptibility results specifically from UV-induced cellular responses.
UV radiation has been shown to induce immunosuppression, identified as a
major risk factor for cancer induction (Beissert & Loser, 2008). Further, UV radiation
specifically causes immune suppression resulting in a susceptibility to UV-induced skin
tumors (Kripke, 1981; Kripke & Morison, 1985).

Interestingly, p53p/p mice were

significantly more susceptible to the immunosuppressive effects of UV radiation, being
observed at very low doses of UVR that did not suppress the delayed type
hypersensitivity in wild-type mice. These results differ from p53-/- mice, which did not
display increased susceptibility to immune suppression compared to wild-type mice
(Jiang et al, 2001). Although different strains of mice exhibit different levels of UVinduced immune suppression (Hart et al, 1998; Noonan & Hoffman, 1994), it is possible
that the strain utilized here (C57BL/6 129/Sv mix) could explain the discrepancy
between the results observed in p53-/- and p53p/p mice. This is, however, unlikely
because the littermate controls in our study did not exhibit the same sensitivity as p53 p/p
mice. Considering we did not observe defects in the repair of UV-induced DNA damage

or other genetic alterations in p16INK4a, p19ARF, and RAS genes in the p53p/p mice (data
not shown), we concluded that the inability to repair DNA damage did not contribute to
the increased susceptibility. Instead, the strong induction of permanently arresting the
cell cycle may be the main contributor to the hypersensitivity after UVB treatment.
Consistent with this notion, a recent study linked chronic UV exposure to the induction
of premature senescence in human skin fibroblasts (Chen et al, 2008), potentially
exacerbating UV-induced photoaging. Further research to investigate the role of p53dependent apoptosis regarding UV-induced inflammation and immunosuppression is
needed. Other p53 mutations may also be linked to immune suppression and possibly
directly connected to tumorigenesis, an area not yet well explored.
The nucleotide excision repair pathways fixes UV-induced DNA damage
(Nouspikel, 2009); as mentioned above, cells with severely damaged DNA undergo
apoptosis—p53 has a central role in both processes (Chang et al, 2008). p53 can bind
certain NER factors and directly participate in DNA damage repair (Ford et al, 1998;
Ford & Hanawalt, 1995) as well as pause the cell cycle to provide ample time for cells to
repair the damage. Further, p53 is necessary to induce programmed cell death after
DNA damage. Unlike p53-deficient fibroblasts that are grossly defective in NER, our
study showed that mutant p53p/p cells have a normal ability to repair DNA after UVR.
This indicates that DNA damage per se is not the sole cause of sensitivity to UV
radiation treatment. How p53 participates during the NER process is still not completely
understood. Specifically, some studies show p53 may directly bind to NER helicase
factors XPD or XPB (Wang et al, 1995), or function in NER by regulating gene
expression, such as XPC or XPE genes (Adimoolam & Ford, 2002; Hwang et al, 1999).

Further, p53 can transactivate genes that encode for the initiation of global genome
repair (Helton & Chen, 2007). Our study indicates that the hypomorphic mutant p53p/p
retains at least a partial function in terms of repairing UV-induced DNA damage.
This study reveals that two p53-dependent events are important for the induction
of apoptosis after UVB exposure: 1. upregulation of pro-apoptotic genes such as PUMA
and Noxa and 2. the downregulation of anti-apoptotic gene Bcl-2, through the
inactivation of the transcriptional factor E2F1 (Knezevic et al, 2007; Wikonkal et al,
2003). Our hypomorphic p53 mutant is defective in both events. These results are
consistent with a previous study reporting that loss of Noxa or PUMA renders MEFs
partially resistant to UV-induced cell death (Naik et al, 2007).

Interestingly,

overexpressing Bcl-2 also inhibits UV-induced apoptosis, which mimics the mutant
p53p/p MEFs after UV radiation. The down regulation of Bcl-2 by RNA interference can
restore the apoptotic response after UVB exposure in p53-/- fibroblasts (Knezevic et al,
2007), indicating that Bcl-2 plays a critical role in deciding this cell fate. It is interesting
to observe that p53p/p fails to transactivate PUMA/Noxa but retains the ability to
upregulate p21 to almost normal levels. Although we don’t know the mechanism, a clue
maybe lie the nature of promoters that p53 regulates. Rrecently, a study showed the
kinetics of genes involved in different cellular responses are expressed differently—
regulators of the cell cycle have “preloaded” promoters and can be activated much faster
than the apoptotic molecules that need to assemble and activate the pre-initiation
complex (Morachis et al, 2010). Therefore it is tempting to speculate, in regard to the
inability of the mutant p53 to transactivate certain promoters could be due either to steric
hindrance presented by the point mutation in the DNA binding domain or perhaps a lack

of consensus sequences needed to bind properly. Regardless, further studies are needed
to understand exactly why the hypomorphic p53p/p cannot transactivate apoptotic
molecules yet retains a partial ability to activate cell cycle regulators. Our data suggests
this maybe why p53p/p cells undergo cellular senescence.
UV and IR exposure inflict different types of DNA damage, which trigger
different responses upstream of p53; this may explain our observation that UVR and not
IR exposure induces MEFs into apoptosis. UV treatment mainly causes modification of
chemical bonds to the DNA bases. Modifications on pyrimidine bases form dimers or
(6-4) photoproducts between C-T bases causing distortions in the chromatin structure
different from the DNA double strand breaks caused by IR. Although they share some
overlapping targets in cell cycle checkpoint activation, ATM and ATR are activated by
different kinds of DNA damage. ATM senses double-strand ends and ATR senses
single stranded DNA bound with RPA (Cimprich & Cortez, 2008). Further, ATR is
activated slower when compared to ATM, which is mainly due to the DNA breaks in
those cells being recognized during the S and G2 phase of the cell cycle. UVB-induced
genomic damage can be sensed via ATR (Unsal-Kacmaz et al, 2002), to activate a Chk1dependent signaling pathway arresting the cell cycle, increasing DNA repair, or
triggering senescence/apoptosis. Relevant to this study, UV and IR radiation leads to
different p53 post-translational modifications. Specifically, UV leads to phosphorylation
at Ser389, while IR does not, resulting in the activation of different downstream
effectors. Interestingly, p53S389A/ S389A mice are more susceptible to tumors after chronic
UV exposure but not after IR exposure (Bruins et al, 2004). Therefore, different types of
DNA damage can modify p53 at specific sites to trigger certain cellular responses.

The cellular response to UVR also differs amongst cell types (D'Errico et al,
2007). Recent studies show that the engagement of ATR-ATRIP with the TOPBP1
molecule triggers the DNA damage response and induces cells to undergo p53dependent senescence (Toledo et al, 2008). This study specifically found that short
transient signaling resulted in cell cycle arrest, whereas longer persistent signaling led to
senescence. Our study shows that UVR treatment leads to apoptosis in wild-type mice
in a dose- and time-dependent fashion, but induced senescence in the absence of
apoptosis. Similar to our p53p/p mutant, where deletion of the proline rich domain of p53,
important for the induction of apoptosis, eliminates the apoptosis pathway but not cell
cycle arrest (Slatter et al, 2010). This mutation changes the tumor spectrum, where the
mutant mice succumb to B-cell lymphoma in comparison with p53 null mice, which
succumb to mostly thymic lymphomas. Most importantly, our work suggests that p53dependent apoptosis, along with DNA repair and cell cycle arrest in response to UVR,
work together to control the proliferation of cells and maintain the genomic integrity.
These responses are necessary to ensure cell homeostasis. A deficiency in one
component, in our case, the apoptotic pathway, may lead to unbalanced cell homeostasis
that might propagate into pathogenic consequences if not suppressed (Tavana et al,
2010a). This study is a clear example of p53-dependent cellular responses, rather than
DNA repair activity per se, which can play a dominant role in the regulation of cell
growth and proliferation.

CHAPTER 4
ABSENCE OF P53-DEPENDENT APOPTOSIS
COMBINED WITH NON-HOMOLOGOUS END
JOINING DEFICIENCY LEAD TO A SEVERE

DIABETIC PHENOTYPE IN MICE

4.1

Introduction
“As mentioned above, classic non-homologous end joining is one of the
two major pathways for the repair of DNA double strand breaks (DSB)
(Mahaney et al, 2009). The factors involved form a DNA recognition complex
composed of DNA-dependent kinase complex, DNA-PKcs, a Ku70/80
heterodimer, and repair factor Artemis. Once the DNA ends are processed, they
are mended together using the DNA ligase complex composed of DNA ligase IV,
XRCC4, and Cernunnos/XLF (Huang et al, 2009). Both DNA ligase IV and
XRCC4 are absolutely required for the classic NHEJ pathway, as their
deficiencies lead to embryonic lethality (Frank et al, 1998; Gao et al, 1998).
Further, global NHEJ deficiencies render cells hypersensitive to DNA damaging
agents, such as ionizing radiation, and premature senescence (Mills et al, 2004).
During V(D)J recombination, programed double strand breaks are introduced
purposely to allow for DNA segment rearrangement of the Variable, Diversity,
and Joining regions—the NHEJ is extremely critical in mending these programed
double strand breaks.

In developing lymphocytes, the abrogation of NHEJ

factors results in the accumulation of unrepaired DNA breaks, which reaches a
threshold and activates p53-mediated apoptosis to eliminate genomic instability.
Spontaneous DNA damage also occurs in other organs, such as the brain and
CNS, and if too excessive, as in the case of DNA Ligase IV or XRCC4
deficiencies, can lead to an exorbitant amount of cells undergoing apoptosis and
cause embryonic lethality (Frank et al, 1998; Gao et al, 1998). This embryonic
lethality is rescued by p53 deficiency (Frank et al, 2000; Gao et al, 2000),

because the apoptotic ability of p53 is deleted. This comes at a cost, because the
cell cycle arrest function of p53 is also deleted, driving aggressive and lethal proB lymphomas at an early age (Figure 15a) (Zhu et al, 2002).

All these

lymphomas carry a chromosomal translocation between the immunoglobulin and
the proto-oncogene c-MYC loci, forming a complicon structure, which leads to
amplification of the MYC genes (Figure 15a). Interestingly, the hypomorphic,
separation-of-function mutant p53p/p (Liu et al, 2004), defective in apoptosis yet
retains a partial cell cycle arrest function, not only rescues embryonic lethality
but also entirely eliminates lymphomagenesis in the Lig4-/- (Figure 15b) (Van
Nguyen et al, 2007). Analyses of Lig4-/-p53p/p tissues revealed extensive cellular
senescence in the developing lymphocytes with increased levels of p53 and p21
(Figure 15c). This indicates that Rag-mediated DSBs, which remain unrepaired
due to the deficiency in end-joining, activate the hypomorphic p53 and putative
downstream target p21, to ultimately drive these cells into cellular senescence.
This p53-p21 driven senescence is proven to be an effective barrier in
suppressing genomic instability and tumorigenesis.

These studies are

summarized in a schematic in Figure 16.
Cellular senescence is a mechanism, which prevents cells to undergo apoptosis
and halts cell proliferation in tissues despite the potent tumor suppressor activity.
These properties can accelerate ageing-related diseases (d'Adda di Fagagna,
2008). Although DNA damage-induced senescence can successfully prevent
lymphomagenesis, all Lig4-/-p53p/p mice have an ageing appearance and die
before they reach 6 months of age (Figure 15b). After analysis of the glucose

levels in the urine of old Lig4-/-p53p/p, we predicted these mice were developing
diabetes. Therefore, we hypothesized that spontaneous DNA damage, like that
occurring in the brain, may also activate p53 and p21 to induce cellular
senescence and decrease cellular proliferation and organ renewal capability. As
a result, the insulin producing cells would not proliferate, and the maintenance of
homeostasis would be compromised. Indeed, we describe the first animal model
that progressively develops diabetes with a depletion of pancreatic -cell mass
due to accumulated DNA damage and a p53-dependent response that drives cells
into senescence. Our model indicates that age-related DNA damage
accumulation in the pancreatic -cells, and its associated senescence, may be one
cause of diabetes (Tavana et al, 2010c).
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Figure 15. Ligase IV deficiency combined with either p53-/- or p53p/p.
(A) Flow cytometric analysis of Lig4+/-p53+/- B-cells or Lig4-/-p53-/- pro-B cell
lymphomas (left panels). FISH of IgH and c-MYC of Lig4-/-p53-/- depicting the
‘breakage-fusion-bridge’ cycle (far right panel). (B) Kaplan-Meier curve or Lig4-/p53p/p (yellow) and Lig4-/-p53-/- (blue). Percent lymphoma incidence in Lig4-/-p53-/and Lig4-/-p53p/p mice (far right panel). (C) Western blot analysis of thymocytes
detecting p53 levels. Representative staining of β-gal in Lig4-/-p53p/p and Lig4-/-p53-/thymic sections (far right panel).
(Modified and reproduced from (Zhu, 2002) and (van Nguyen, 2007) with permission from
Cell and Journal of Experimental Medicine, respectively)

4.2

Results

4.2.1 Lig4-/-p53p/p mice exhibit glucose intolerance and impaired insulin
production.
Previously, we showed that Lig4-/-p53p/p mice do not develop lymphomas or any
other type of tumors, yet die within 6 months of age (Figure 15b) (Van Nguyen
et al, 2007). Aged mutant mice often appeared emaciated and lethargic prior to
death. Analyzing the cause of death, the Veterinary Medicine Department of
MDACC observed high levels of glucose in the urine of a 5-month old Lig4-/p53p/p mouse. To confirm this data, we monitored glucose levels in the urine
over time.

As shown in Figure 17a, Lig4-/-p53p/p mice presented increased

glucose levels in the urine as early as 1 month, reaching up to 1000mg/dL as
early as 2 months and increased beyond the limit of the assay at 4 months when
compared to aged-matched wild-type and p53p/p controls. For a more accurate
measurement, we monitored the blood glucose levels in non-fasting Lig4-/-p53p/p
mice at different ages and found a progressive increase in blood glucose levels,
which was significantly different (p<0.005) from the levels detected in agematched wild-type mice (Figure 17b). Significant hyperglycemia was recorded as
early as 2-month of age, suggesting a time-delayed postnatal development of
diabetes in the Lig4-/-p53p/p mice.
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Figure 16. p53-dependent outcomes in the lymphoid system in the absence of
NHEJ. During V(D)J recombination, Rag1/2 recognizes and cleaves DNA in double
strand breaks (DSBs) at the recombination signal sequences (triangles). In a NHEJdependent manner, the hairpins are broken and merged together forming a coding
end. In the absence of NHEJ, DNA DSBs remain and persist. The accumulation of
unrepaired DSBs activates wild-type p53 (p53+/+) to initiate apoptosis—a known
mechanism to prevent tumorigenesis. In the absence of p53 (p53-/-) cell cycle arrest
and apoptotic functions are lost, and cells proliferate even with the persistent DNA
damage. This leads to chromosomal translocations and tumorigenesis. Introducing a
hypomorphic, separation-of-function mutant (p53p/p), where apoptosis is abrogated
yet cell cycle arrest remains intact, p53 triggers cellular senescence, which is in
parallel to apoptosis, as a formidable barrier to tumorigenesis.

To determine the onset of diabetes, we performed a standard glucose
tolerance test in both 1- and 3-month old mutant mice with age-matched wildtype mice as controls. The glucose tolerance test at 1-month of age did not
exhibit a significant difference between the two groups (Figure 18a).
Additionally, there was no significant difference in the secretion of insulin after
glucose stimulation, as determined by ELISA (Figure 18b), depicting that 1month old Lig4-/-p53p/p pancreatic β-cells have no problems. However, 3-month
old Lig4-/-p53p/p mice showed hyperglycemia at the start point; after the glucose
injection, the levels increased and were not readily cleared during the assay
(Figure 18c). These results indicate a progressive impaired glucose tolerance and
diabetes in the mutant mice. To determine the ability of pancreatic β-cells to
secrete insulin upon glucose stimulation, we performed ELISA assays to
determine the blood insulin levels in these mice. Unlike 1-month mutant mice,
insulin levels in the 3-month old mutant mice were significantly lower (p<0.005)
and were irresponsive to the glucose injection, suggesting insulin insufficiency in
these mice (Figure 18d). Next, to determine if the overt diabetes was a cause of
insulin resistance, we preformed an insulin tolerance test performed on 1-month
and 3-month old mutant and wild-type mice, independently, which revealed no
differences between the two genotypes, indicating normal insulin sensitivity prior
to the onset of diabetes (Figure 18e and 18f). Collectively, these results indicate
that Lig4-/-p53p/p mice progressively develop diabetes due to an insufficient
production of insulin, which results in impaired glucose tolerance.
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Figure 17. Lig4-/-p53p/p mice progressively develop hyperglycemia
(A) Glucose levels in the urine were measured (mg/dL) over time in wild-type, Lig4+/
+p53p/p and Lig4-/-p53p/p mice. (B) Glucose levels in the blood were measured (mg/
dL) over time in wild-type (red circles) and Lig4-/-p53p/p (blue squares) non-fasting
mice. Each data point was an average of at least three animals. * represents p<0.0001
versus wild-type.
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)
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Figure 18. Lig4-/-p53p/p mice are glucose intolerant but not insulin resistant.
Blood glucose concentrations measured from a glucose tolerance test in wild-type
and Lig4-/-p53p/p mice at 1 (A) and 3 (C) months. Blood insulin concentrations were
measured by ELISA at 1 (B) and 3 (D) months. Standard ITT test for insulin
sensitivity in 1 (E) and 3 (F) month old wild-type and Lig4-/-p53p/p mice. A minimum
of three mice from each genotype were tested. * represents p<0.005 versus wild-type.
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)

4.2.2 Progressive depletion of pancreatic -cells in Lig4-/-p53p/p mice.
Insulin insufficiency due to pancreatic -cell attrition is a common
characteristic in both types of diabetes. Type I diabetes results from the
combined effects of environmental, genetic, and predominantly immunological
factors that destroy pancreatic -cells (Kukreja & Maclaren, 1999). Type 2
diabetes results from a progressive islet dysfunction leading to defective -cell
secretion and insulin resistance (DeFronzo, 1997; Karaca et al, 2009). In both
cases, -cell mass decreases. Although residual functional -cells still exists,
they are insufficient in number to maintain glucose tolerance. To determine
whether the hyperglycemia and lowered insulin secretion observed in the Lig4-/p53p/p mice was the result of a progressive decrease in -cell mass, we examined
the morphological changes in the pancreatic islets immunohistochemical staining
for insulin. As shown in Figure 19a, mutant mice have a relatively normal size
of pancreatic islets as compared to the wild-type at 1 week after birth. However,
as mutant mice aged the size of the pancreatic islets gradually declined. A
drastic involution in islet size was observed in the mutant mice as early as 1
month of age. At 5 months, an almost complete depletion of the pancreatic islets
was observed. To quantitatively measure and assess the differences of -cell
mass in Lig4-/-p53p/p and wild-type mice, we determined the ratio of islet area to
total pancreas area. Islet size was nearly normal at 1 week of age (p<0.25)
(Figure 19b). In general, older mutant mice observed a drastic reduction in
pancreatic islet area. A 46% reduction in islet area was observed in the mutant
mice at 1 month (p<0.0001); by 5 months, a 73% decrease was observed in the

mutant mice (p<0.0001). Further immunohistochemical staining for glucagon,
indicative of -cells which signal the liver to breakdown glycogen and produce
glucose upon hypoglycemic conditions, did not reveal any abnormalities in these
mutant mice, yet still show islet attrition (Figure 20a). Lastly, although the
measuring of islet area to total pancreatic area is a proportion, the possibility of
Lig4-/-p53p/p mice having a smaller pancreas was ruled out through analyzing the
ratio of pancreas-to-body weight between mutant and wild-type mice (Figure
20b). Collectively, these results clearly indicate a severe diminishment of the
pancreatic islet mass in Lig4-/-p53p/p mice, which directly correlates with the
progressive onset of diabetics observed.
4.2.3 The depletion of the pancreatic islets is not due to apoptosis or innate
immunity.
The depletion of pancreatic islets in type I diabetes is mainly
caused by activated immune cells specifically attacking -cells. This is unlikely
to happen in the Lig4-/-p53p/p mice as the deficiency in NHEJ depletes all
lymphocytes due to incomplete V(D)J recombination. Therefore, we examined
whether the innate immunity branch has any involvement in -cell depletion.
Pancreatic sections from different ages were stained for a CD11b surface marker,
to identify any infiltrated granulocytes, monocytes, dendritic cells or natural
killer cells. Few cells were stained positive for CD11b in either Lig4-/-p53p/p or
wild-type pancreatic sections, while many cells were CD11b positive in the
control spleen section (Figure 21).
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Figure 19. A progressive decrease is islet mass observed in Lig4-/-p53p/p mice.
(A) Representative pancreatic sections from Lig4-/-p53p/p and wild-type mice stained
by immunohistochemistry for insulin at indicated time points. Magnification: 40X.
(B) Islet morphometric quantification of Lig4-/-p53p/p and wild-type mice. Multiple
sections were analyzed for each pancreas, and 3-4 mice per group were analyzed,
data represent the mean ± SEM; * represents p<0.0001 versus wild-type.
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)

We also stained for F4-80 and Toluidine blue, a marker of infiltrated
macrophages and mast, respectively. Similar to CD11b staining, macrophage
and Toluidine blue-positive cells were rarely detected in pancreatic sections in
both genotypes (Figure 21). These results suggest that it is unlikely innate
immunity is responsible for the destruction of the Lig4 -/-p53p/p pancreatic islets.
Many diabetic models with resulting -cell loss occur from an increase in isletspecific apoptosis (Butler et al, 2003; Scaglia et al, 1997). Although the p53R172P
mutation prevents the induction of p53-mediated apoptosis, programmed cell
death in pancreatic islets may occur independently of p53 expression (Nam et al,
2008).

To test whether apoptosis is causing the pancreatic islet depletion

observed in Lig4-/-p53p/p mice, we performed a TUNEL assay in pancreatic
sections. Apoptosis was not observed in 3-month mutant pancreatic sections
while only a very low level of apoptosis was observed in wild-type as compared
to a NHEJ deficient thymus section (Figure 22). Similar results were obtained
with mice at different ages (results not shown).

These data suggest that

pancreatic islet depletion observed in the Lig4-/-p53p/p mice is not due to
apoptosis.
4.2.4 Decreased proliferation of -cells in Lig4-/-p53p/p mice.
The genesis of adult insulin-producing -cells predominantly occurs
through self-duplication of mature cells rather than through differentiation from
their stem-cell progenitors (Dor et al, 2004; Georgia & Bhushan, 2004; Salpeter
et al, 2010; Teta et al, 2007).
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Figure 20. No decreases in alpha-cells or total pancreas size in Lig4-/-p53p/p mice.
(A) Representative pancreatic sections from Lig4-/-p53p/p and wild-type mice were
immunohistochemically stained with anti-glucagon. Magnification: 40X. (B) The
total weight of Lig4-/-p53p/p and wild-type mice were divided by the weight of their
respective pancreata and the ratio was recorded. No statistical differences were
noted.
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)

Without compensatory -cell replication, abrogating the -cell cycle
leads to a decrease in islet mass, consequentially reducing insulin
production, which deregulates glucose homeostasis, and ultimately drives
hyperglycemia and overt diabetes (reviewed in detail (Tavana & Zhu,
2011)). Therefore, we hypothesized that the diminishment of islets seen
in the Lig4-/-p53p/p islets could be due to decreased proliferation rates,
thereby decreasing the production of other -cells.

To test this

hypothesis, we compared the -cell proliferation rates by BrdU
incorporation.

Proliferating pancreatic cells,

dually positive for

incorporated BrdU and insulin, were identified by immunostaining. This
number was divided by cells positive for only insulin, to get the ratio of
proliferating -cells. As shown in Figures 23a and 23b, no differences in
proliferation rates were observed at one week of age, but a discrete nonsignificant 28% decrease (p<0.285) in -cell proliferation was observed
in 1-month Lig4-/-p53p/p pancreas.

A significant decrease by 60%

(p<0.0001) and 62% (p<0.05) in -cell proliferation was observed in both
2- and 3-month old mutant mice, respectively, as opposed to their wildtype controls. These results strongly correlate with the time-dependent
appearance of the diabetic phenotype, suggesting a direct relationship
between the decline in the -cell proliferation and the onset of diabetes.
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Figure 21. Observed islet depletion is not due to innate immunity infiltration.
Pancreatic sections from Lig4-/-p53p/p and wild-type mice were stained for Cd11b (top
panels) or F4-80 (middle panels) with wild-type spleen and bone marrow as
respective controls. Toluidine blue staining was used to indicate mast cells (bottom
panels). Magnification: 40X.
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)
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Figure 22. Observed islet depletion is not due to increased apoptosis.
Pancreatic sections from Lig4-/-p53p/p and wild-type mice were analyzed with a
TUNEL assay; no apoptotic cells detected in pancreata or thymic sections of Lig4-/p53p/p mice. A NHEJ-/- (Artemis deficient) thymus was used as a positive control.
Magnification: 10X
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)

4.2.5

Accumulated DNA damage in the pancreas of Lig4-/-p53p/p mutant

mice.
Due to high energy-consumption, pancreatic -cells are particularly
susceptible to DNA damages caused by intrinsic metabolic agents
including reactive oxygen species (Lenzen, 2008). After sensing DNA
damage, cells will arrest their cycling, in order to fix the broken DNA;
therefore, it is absolutely vital to have an efficient DNA damage repair
machinery to maintain the integrity of the genome. We hypothesized that
in the absence of the NHEJ pathway, pancreatic -cells will have an
accumulation of unrepaired DNA damage. To determine whether H2AX
foci, a common marker indicative of DNA damage, accumulates in the
mutant pancreas, we stained 2- and 4-month old pancreatic sections from
Lig4-/-p53p/p and wild-type mice. H2AX foci were detected throughout
the 2-month old mutant but not in the wild-type sections. At 4 months,
intense H2AX foci was observed in most mutant pancreatic -cells,
indicating DNA damage was accumulating; this is in clear contrast to the
absence of foci observed in the wild-type pancreas (Figure 24). These
results indicate that in the absence of classic NHEJ, pancreatic islets
suffer from gross accumulative DNA damage.
4.2.6 DNA damage-induced p53/p21 axis results in cellular senescence in the Lig4/-

p53p/p islets.
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Figure 23. Decreased b-cells proliferation in Lig4-/-p53p/p mice.
(A) Percent of BrdU incorporation in b-cells out of the total b-cells was measured in
each age group of Lig4-/-p53p/p mice, and plotted in comparison with age-matched
wild-type mice. N≥2 mice per time point. Data are the mean ± SEM, * indicates
p<0.05 versus wild-type. (B) Representative islet proliferation of pancreatic sections
incubated with anti-BrdU antibody (green) and co-stained with anti-insulin antibody
(red). Arrows indicated BrdU positive cells. Magnification 40X.
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)

Previously, we reported in the lymphoid system, programed DNA double
strand breaks will accumulate, in the absence of NHEJ, which leads to the
activation of p53 and p21 (Van Nguyen et al, 2007).
Therefore, to asses if the accumulation of DNA damage in pancreatic cells could stimulate p53 and p21 expression, we used immunostaining.
Since DNA damage occurs randomly in the pancreas, as opposed to the
programmed DNA damage in developing lymphocytes, we did not detect
as strong of an expression of p53 and p21. However, the p53/p21 axis
was activated in some pancreatic islets of Lig4-/-p53p/p mice (Figure 25).
Virtually neither p53 nor p21 were detected in age-matched wild-type
pancreatic sections. These results indicated that accumulated DNA
damage induces a p53-p21 dependent response in the pancreas of the
Lig4-/-p53p/p mice.
Activating the p53/p21 axis promotes cellular senescence as a mechanism
to suppress genome instability and tumorigenesis, as show previously in
the lymphoid system (Van Nguyen et al, 2007). Therefore, we asked
whether the random accumulation of DNA damage, which induces p53p21 activation, could render pancreatic -cells to undergo cellular
senescence.

Pancreata from mutant and age-matched wild-type mice

were stained for -galactosidase (-gal) activity, which indicates cellular
senescence. Dual staining of -gal and insulin demonstrated that at all
three time points indicated in Lig4-/-p53p/p mice, islet senescence was
induced (Figure 26). Importantly, no senescent cells were detected in
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Figure 24. Accumulation of DNA damage in Lig4-/-p53p/p mice.
Pancreatic sections immunofluorescent stained for insulin (red), gH2AX foci (green),
and DAPI (blue) in 2- and 4 month Lig4-/-p53p/p and wild-type mice. Magnification
100X.
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)

age-matched wild-type pancreatic sections. Collectively, these results
indicate that the accumulation of spontaneous DNA damage, caused from
the DNA Ligase IV deficiency, was sufficient to activate p53/p21 and
trigger cellular senescence in mutant -cells. This permanent arrest lead
to the decrease of insulin production and dysregulated glucose
homeostatsis ultimately driving the diabetic phenotype observed (Tavana
et al, 2010c). Remarkably, while DNA damage induction of p53-p21 and
senescence is beneficial in the developing lymphocytes by suppressing
genomic instability and preventing tumorigenesis, senescence in the
pancreatic -cells acts as a double-edged sword, leading to a depletion of
islets and insulin insufficiency, resulting in diabetes.

4.3

Discussion
This study presents a unique animal model where accumulating DNA
damage, due to a deficiency of end-joining (DNA Ligase IV), leads to upregulation of p53-p21 and senescence in pancreatic -cells. This p53 activation
diminishes the self-replication capability of -cells, resulting in a drastic loss in
pancreatic islet number ultimately driving diabetes (Tavana et al, 2010c). Our
animal model further emphasizes the importance of regulating cellular replication
in already differentiated -cells to maintain the homeostasis of islet mass and
glucose metabolism. This is also a unique animal model that is the first to
directly implicate the accumulation of DNA damage due to impaired DNA repair,

a typical phenotype of ageing, leading to the onset of diabetes. Therefore, this is
significant for our understanding of diabetogenesis and offers potential insight
into future therapies. Diabetes occurs when -cells fail to produce sufficient
insulin for metabolic demands, due to their dysfunction or simply a failure to
maintain the islet cell mass which automatically will decrease the insulin
production (Ackermann & Gannon, 2007; Masiello, 2006). In adult mice, -cell
mass is maintained by self-replication rather than differentiation from stem cells
or neogenesis (Dor et al, 2004; Georgia & Bhushan, 2004). Therefore, factors
mediating -cell proliferation directly impact their maintenance. Mice deficient
for these regulatory factors have defective -cell replication directly leading to a
reduction in cell number and the development of diabetes (reviewed in detail
(Tavana & Zhu, 2011)). Such examples are CDK4 (Rane et al, 1999; Tsutsui et
al, 1999) or Cyclin D2 deficient mice (Georgia & Bhushan, 2004; Kushner et al,
2005); both models have a progressive reduction of -cell number and gross
onset of diabetes with features of hyperglycemia and glucose intolerance.
Conversely, overexpression of CDK4 (Rane et al, 1999) or Cyclin D1 (Zhang et
al, 2005) in pancreatic -cells leads to hyperplasia of pancreatic islet cells,
indicating the importance of these key molecules, underscoring the critical role
of cell proliferation in the maintenance of -cells. Our results are inline with
these models. Furthermore, it appears that adulthood and neonatal -cell
maintenance is dictated through different mechanisms. While both CDK4 and
Cyclin D2 deficient newborn pups have relatively normal pancreatic islet mass, a
progressive reduction in -cell number occurs upon animal age. The Lig4-/-p53p/p

mice have a similar pattern of the progressive development of diabetes, strongly
suggesting that reduction in -cell proliferation directly leads to the decrease in
-cell numbers and resulting in severe diabetes (Tavana et al, 2010c).
Additionally, Cyclin dependent kinase inhibitors, the Cip and Kip protein family
along with the INK4/ARF group, play essential roles in directly regulating -cell
proliferation (Tavana & Zhu, 2011) and therefore impact -cell maintenance.
Overexpression of p27kip1 (Uchida et al, 2005) or p16INK4a (Krishnamurthy et al,
2006) directly leads to a decrease in the rate of -cell proliferation and a
reduction in -cell mass. Conversely, p16INK4a (Krishnamurthy et al, 2006),
p27kip1, or p18INK4c (Rachdi et al, 2006) deficiency results in pancreatic islet
hyperplasia. These results indicate that CDK inhibitors are important regulators
of cell proliferation in the pancreatic -cells. While cell cycle inhibitor and
putative p53 downstream target p21 is expressed in pancreatic -cells (CozarCastellano et al, 2006b; Cozar-Castellano et al, 2006c), islets grow and function
normally in the absence of p21, suggesting that other cell cycle inhibitors may
function to compensate for the p21 deficiency. Interestingly, p21 is upregulated
in murine pancreatic islets by overexpressing potent mitogens such as placental
lactogene (PL) or hepatocyte growth factor (HGF), depicting the importance of
p21 in inhibiting growth factor-driven proliferation in murine islets. Therefore,
p21, although not vital for normal -cell proliferation or function, plays an
important role when -cells exhibit stress.
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Figure 25. Elevated p53 and p21 in Lig4-/-p53p/p islets.
(A) Double immunohistochemical staining of pancreatic sections from 3-month old
Lig4-/-p53p/p and wild-type mice for p53 (black) and insulin (orange). (B) Double
immunohistochemical staining of pancreatic sections from 3-month old Lig4-/-p53p/p
and wild-type mice for p21 (black) in combination with insulin (red). Magnification
40X.
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)
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Figure 26. Increased cellular senescence in Lig4-/-p53p/p islets.
Immunohistochemical staining for insulin (brown) and b-galactosidase (blue)
staining of pancreatic sections from age-matched Lig4-/-p53p/p and wild-type mice.
Counterstaining with Nuclear Fast Red. Magnification 100X.
(Modified and reproduced from (Tavana, 2010) with permission from Diabetes)

Previously, our study demonstrated that in the response to genetically
programmed DNA damage, p53 and its downstream target p21 are critical to
drive cells into cell cycle arrest and senescence in the developing lymphocytes
(Van Nguyen et al, 2007). Interestingly, in this study, the same DNA damage
responsive pathway is activated, to also drive -cells into senescence. Such a
strong inhibitory mechanism of cell proliferation plays a pivotal role blocking cell proliferation. The maintenance of cellular homeostasis is dependent on
strictly regulating cellular proliferation, and the tumor suppressor p53, which
plays a key role during this regulation. The NHEJ deficient mice are unique
models, which aptly demonstrate this concept. Deleting p53 combined with the
deficiency of NHEJ leads to rapid tumorigenesis in developing lymphoid cells,
due to the presence of unrepaired physiological DNA breaks in proliferating cells
which lead to chromosomal translocation and subsequent oncogene activation
(Difilippantonio et al, 2002; Zhu et al, 2002).

The separation-of-function,

hypomorphic p53R172P successfully rescued tumorigenesis because p53 activity is
able to respond to physiological or other spontaneous DNA damages and block
cellular proliferation to prevent genomic instability.

But this potent tumor

suppression mechanism comes with a price; this theory has been coined as
‘antagonistic pleiotropy’(Kirkwood & Austad, 2000).

Basically, cellular

senescence can prevent tumorigenesis, but over time, in renewable organs, it
leads to deleterious effects (Campisi, 2003), which is evident in our unique
animal model.

We propose that the persistent DNA damage due to NHEJ

deficiency leads to p53-dependent senescence (in the absence of apoptosis), a

program that requires cells to undergo dramatic chromatin remodeling. Further,
cells will shut down any DNA replication, preventing the cells to re-enter the cell
cycle. Cellular senescence leads to the silencing of many genes related to cell
growth and metabolism. This accumulative event exacerbates the ageing process,
which is deleterious to those organs that require constant renewal through
regeneration, such as in pancreatic islets. Further, we propose that Lig4-/-p53p/p
mice develop diabetes due to an incapability of -cell proliferation and a failure
to maintain -cell mass to a certain threshold. Accumulative DNA damage and
subsequent p53-induced senescence may be the main contribution to the
inhibition of -cell proliferation. However, we cannot rule out other effects
accompanying senescence, such as the silencing of critical genes required for
sensing growth signals, which can lead to -cell irresponsiveness.

Further

investigation is required to address this matter. Additionally, there must be a
mechanism to remove the senescence cells which caused the severe reduction of
-cell number in 3 month and older mutant mice by means other than apoptosis.
Scott Lowe’s group showed that senescent tumors are eradicated through the
innate immune system (Xue et al, 2007). Because we did not see any infiltrating
immune cells, this may not be the case for our model. Other studies have
introduced autophagy to potentially play a role in clearing out senescent cells to
recycle and reuse proteins/nutrients; further investigation is needed. Similar
results have been recently reported on mice deficient for the pituitary tumor
transforming gene (PTTG).

Interestingly, deficiency of PTTG leads to a

progressive up-regulation of p21 that drives pancreatic beta cells into senescence
that eventually results in insulinopenic diabetes (Chesnokova et al, 2009).
It has been hypothesized that the accumulation of DNA damage and the
activated cellular response are both potential contributing factors for ageing
(Campisi & Vijg, 2009). Consistent with this hypothesis, our study using this
unique animal model showed that accumulation of DNA damage and its p53dependent responses have a profound impact on the rate of proliferation in
pancreatic -cells. This is p53-dependent, as the Lig4-/-p53-/- mice do not show
an increase in blood glucose (Tavana unpublished data), even though they do
succumb to rapid tumorigenesis around 2 months (Zhu et al, 2002). Deficiency
in DNA damage repair factors obviously accelerates the accumulation of DNA
damage. Spontaneous damage can occur frequently in pancreatic -cells (Lenzen,
2008), making NHEJ activity important to repair the damage and to maintain the
integrity of the genome. It is the mutation in the DNA damage response that
gradually leads to the halting of the cellular proliferation. Diabetes incidence
increases upon age, and the NHEJ pathway activity decreases among age. There
may be a previously overlooked association that needs to be explored.
Accumulating DNA damage and gene mutations, both require a long process to
develop and could be a major ageing causative factor. Interestingly, this study
highlights the importance of p21 in regulating -cell proliferation upon excessive
genomic stress. DNA damage-induced cellular senescence is a potent tumor
suppressing mechanism, but also diminishes the regeneration and renewal
capacity of certain organs. This can lead to ageing-related diseases, such as

diabetes with depletion of pancreatic islet mass causing lower insulin to regulate
glucose homeostatsis” (Tavana et al, 2010b).

CHAPTER 5
ABSENCE OF KU70 LEADS TO INCREASED ΒETA
CELL PROLIFERATION AND HYPOGLYCEMIA—
A NOVEL NHEJ-INDEPENDENT FUNCTION.

5.1

Introduction
The inability to maintain genomic stability and control proliferation are

hallmarks of many cancers, which are exacerbated in the presence of unrepaired DNA
damage. One of the major pathways that repair DNA double strand breaks (DSBs) is
non-homologous end joining (Mahaney et al, 2009). Classically, the NHEJ pathway
mends DSBs in two steps: initially, broken DNA ends are recognized and processed,
initiated by the Ku70/80 heterodimer, which recruits DNA-dependent protein kinase and
repair factor Artemis; next, the DNA is ligated through a complex consisting of a DNA
Ligase IV (Lig4), XRCC4, and Cernunnos/XLF (Mahaney et al, 2009). Previously, by
utilizing a hypomorphic, separation-of-function p53 mutant, p53R172P, which prevents
p53-mediated apoptosis yet retains a partial cell cycle arrest function (Liu et al, 2004),
combined with NHEJ deficiency (Lig4-/-p53p/p), we showed that mutant p53 not only
rescues embryonic lethality but also entirely eliminated lymphomagenesis in the Ligase
IV deficiency (Van Nguyen et al, 2007). Further analyzing developing lymphocytes
revealed the broken DNA ends activated a permanent cell cycle arrest, termed cellular
senescence, which acts in parallel to apoptosis in suppressing tumorigenesis (Van
Nguyen et al, 2007).
Although completely free of tumors, Lig4-/-p53p/p mice succumb to progressive
and severe diabetes (Tavana et al, 2010c).

Mechanistic analysis revealed that

spontaneous DNA damage specifically accumulated in the insulin producing β-cells of
the pancreas, activating the p53/p21 axis to trigger cellular senescence. This cascade
halted the proliferation of β-cells, decreased islet mass, and compromised glucose
homeostasis causing the severe diabetic phenotype (Tavana et al, 2010c). This study

highlighted a crucial role for the NHEJ pathway in preventing the accumulation of
broken DNA and subsequent activation of cell cycle control in pancreatic β-cells.
The genesis of adult insulin-producing -cells predominantly occurs through
self-duplication of mature cells rather than through differentiation from their stem-cell
progenitors (Dor et al, 2004; Georgia & Bhushan, 2004; Salpeter et al, 2010; Teta et al,
2007). Without compensatory -cell replication, abrogating the -cell cycle leads to a
decrease in islet mass, consequentially reducing insulin production, which deregulates
glucose homeostasis, and ultimately drives hyperglycemia and overt diabetes.
Conversely, augmentation of the -cell cycle increases islet area and insulin production,
many times rescuing a diabetic phenotype, yet in some cases results in hypoglycemia
and islet hyperplasia (reviewed in detail (Tavana & Zhu, 2011)). Components of cell
cycle responsible for proliferation are vital in the maintenance of adult -cells, but less is
known about their upstream activators. One such pathway responsible for both pancreas
development and control of postnatal -cells is the canonical Wnt signaling pathway
(Puri & Hebrok, 2010; Welters & Kulkarni, 2008). Activation of Wnt signaling, through
the stabilization of -catenin, has been recently shown to increase -cell proliferation
and elevated serum insulin levels (Heiser et al, 2006; Rulifson et al, 2007). Conversely,
increasing -catenin inhibitors lead to decreased -cell proliferation levels (Dessimoz et
al, 2005; Liu et al, 2008; Rulifson et al, 2007). Collectively, these studies, along with
others, suggest that Wnt signaling plays a critical role in controlling -cell proliferation.
Considering our previous work highlighting the importance of DNA Ligase IV in
preventing genomic instability in pancreatic -cells (Tavana et al, 2010c), we sought to
examine the role of a different NHEJ factor, specifically Ku70, in both the wild-type and

mutant p53, Ku70-/-p53p/p, backgrounds in this study. Although most notable for its role
in DNA damage recognition and repair within the NHEJ pathway, Ku70 has been
implicated in many fundamental, yet different cellular networks (Downs & Jackson,
2004).

Ku70 has been shown to play both direct and indirect roles in telomere

maintenance (Bailey et al, 1999; Bertuch & Lundblad, 2003; Roy et al, 2004; Stellwagen
et al, 2003), apoptosis (Amsel et al, 2008; De Zio et al, 2010; Sawada et al, 2003), and
transcriptional regulation (Brenkman et al, 2010; De Zio et al, 2010; Giffin et al, 1996;
Grote et al, 2006; Idogawa et al, 2007; Lebrun et al, 2005; Nolens et al, 2009). Through
generation and analysis of both Ku70-/- and Ku70-/-p53p/p mice, we surprisingly
discovered that the deficiency for Ku70 progressively developed hypoglycemia. Further
analysis revealed augmented -cell replication and increased islet mass, which is in stark
contrast to that observed in Lig4 deficiency. Mechanistic studies revealed a stabilization
of islet-specific -catenin with increased markers for cell cycle progression;
tumorigenesis was prevented by the induction of islet-specific cellular senescence.
Therefore, in addition to DNA damage repair, Ku70 has a previously undiscovered
function independent of DNA end-joining, which has a direct impact on the proliferation
of pancreatic -cells.

5.2

Results

5.2.1 Ku70-/- and Ku70-/-p53p/p mutant mice exhibit hypoglycemia, increased
insulin levels and glucose tolerance.
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Figure 27. Ku70-/- and Ku70-/-p53p/p mice are hypoglycemic and glucose tolerant.
(A) Blood glucose concentrations from non-fasting animals at indicated ages.
Glucose levels were significantly lower in mutant mice starting around 4 months of
age. Each data point is an average of at least five animals. (B) Blood insulin
concentrations were measured by ELISA at 7 months of age. Each column is an
average of three animals ran in duplicates. (C) Blood glucose concentrations
measured from a glucose tolerance test in old wild-type, Ku70-/- and Ku70-/-p53p/p
mice. Four mice from each genotype were tested. (D) Blood insulin concentrations
were measured by ELISA from the GTT.

Examining the random non-fasting serum glucose levels in Ku70-/- and Ku70-/p53p/p mice revealed progressive hypoglycemia in aged mutant mice. The decrease in
blood glucose levels became significant starting at 4 months in both mutant mice—more
specifically, 7 month Ku70-/- and Ku70-/-p53p/p mice displayed an 89% and 84%
decrease, respectively, in blood glucose levels when compared to age-matched wild-type
controls (p<0.005) (Figure 27a). To measure the non-fasting serum insulin levels, we
performed ELISA assays in 7 month old mice and found significantly higher levels in
both mutant mice (p<0.005) resulting in a 26-35% increase (Figure 27b), suggesting an
imbalance in pancreatic β-cell regulation.
Routine glucose tolerance tests were preformed in young (data not shown) and
older mice (6 months). Besides a lower fasting serum glucose level in mutant mice, no
significant differences were seen between mutant mice when compared to wild-type
controls after glucose injection (Figure 27c), indicating normal glucose tolerance.
Interestingly, ELISA assays to determine blood insulin levels upon glucose stimulation
showed higher levels of secreted serum insulin in both aged Ku70-/- and Ku70-/-p53p/p
mice (Figure 27d). Collectively, the increase in random serum insulin levels in the
mutant mice, driving the hypoglycemia, suggested analyzing islet size and β-cell
proliferation.

5.2.2 Ku70 deficiency results in -cell mass expansion.
To determine whether the hypoglycemia and increased serum insulin
concentrations observed in both Ku70-/- and Ku70-/-p53p/p mice was the result of
increased -cell mass, we examined the morphological changes in the pancreatic islets
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Figure 28. Ku70-/- and Ku70-/-p53p/p mice present augmented pancreatic islet
mass. (A) Representative pancreatic sections from medium aged mice stained by
immunohistochemistry for insulin. Magnification: 10X. (B) Islet morphometric
quantification of wild-type, Ku70-/- and Ku70-/-p53p/p mice. Multiple sections were
analyzed for each pancreas, and 3-4 mice per group were analyzed; data represent the
mean ± SEM. * represents p<0.05-0.005 versus WT.

Percent of body weight

A

B

0.6

0.4

WT
Ku-/Ku-/-PP

0.2

0.0

WT

Ku-/-

Ku-/-PP

Y

M

O
50µm

Figure 29. No decreases in alpha-cells or total pancreas size in the absence of
Ku70. (A) The total weight of Ku70-/-, Ku70-/-p53p/p and wild-type mice were divided
by the weight of their respective pancreata and the ratio was recorded. No statistical
differences were noted. n ≥ 8 per group. (B) Representative pancreatic sections from
wild-type, Ku70 -/- , and Ku70 -/- p53 p/p mice at different ages were
immunohistochemically stained using an anti-glucagon antibody (brown).
Magnification: 40X

by systematically measured the differences of -cell mass in mutant and wild-type mice,
by determining the ratio of islet area (immunohistochemical staining positive for insulin)
divided by total pancreas area (Tavana et al, 2010c). For comparison purposes, we
divided the mice into three age groups: young (2weeks-2.0 months), medium (2.5-4.0
months) and old (4.5-7.0 months).
As shown through representative pictures and quantification in Figures 28a and
28b, young mutant mice have a larger islet to total pancreas ratio as compared to the agematched wild-type controls. As the mutant mice aged, the size of the pancreatic islets
further increased, almost doubling the size of aged wild-type mice (p<0.05-0.005). The
increase in mutant islets was independent of the total pancreas increasing since there was
no significant difference in the ratio of total pancreas weight to body mass (Figure 29a).
Immunohistochemical staining for glucagon, indicative of -cells that signal the
liver to breakdown glycogen to produce glucose upon hypoglycemia, did not reveal any
stark abnormalities in either mutant backgrounds at any time point when compared to
age-matched wild-type controls (Figure 29b).

These results clearly indicate a

progressive augmentation of pancreatic islet mass in the absence of Ku70, which
correlates with the increased insulin production and hypoglycemic phenotype.
5.2.3 Increased islet mass due to -cell hyper-proliferation and increased Cdk4
levels in both Ku70-/- and Ku70-/-p53p/p mice.
The production of adult -cells predominantly occurs through self-duplication of
mature cells giving rise to new -cells rather than through differentiation of their stemcell progenitors (Dor et al, 2004; Georgia & Bhushan, 2004; Teta et al, 2007). Therefore,
we hypothesized that the increased islet mass observed in the mutant mice
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Figure 30. Increased b-cell proliferation in Ku70-/- and Ku70-/-p53p/p islets.
(A) Percent of PCNA incorporation in b-cells out of the total b-cells was measured in
each age group of Ku70-/- and Ku70-/-p53p/p islets, and plotted in comparison with
age-matched wild-type mice. Each column is an average of five mice. Data are the
mean ± SEM, * indicates p<0.005 versus WT. (B) Representative sections of islet
proliferation incubated with an anti-PCNA antibody (brown) and counterstained with
H&E. Arrows indicate PCNA positive cells. Magnification 40X.

was attributed to heightened -cell proliferation. By staining pancreatic sections for
proliferating cell nuclear antigen (PCNA), counting the positive -cells and dividing by
the total number of -cells, we can quantitatively assess the rate of -cell proliferation.
As shown in Figures 30a and 30b young mutant mice show a -cell specific, hyperproliferative phenotype presenting with 59-63% of an increase when compared with agematched wild-type mice (p<0.001). Although showing a similar trend of decreased cell proliferation with age as in wild-type mice, -cell proliferation was significantly
higher in both aged Ku70-/- and Ku70-/-p53p/p mice (p<0.005). Increased proliferation in
young mutant mice was additionally confirmed through Ki67 staining (data not shown).
Further, elevated PCNA staining was not seen in Lig4-/-p53p/p mutant sections, indicating
that the PCNA positive cells observed in the absence of Ku70 is not a result of
accumulated DNA damage. These results strongly correlate with the hypoglycemic
phenotype, indicating a relationship between the absence of Ku70 and increased -cell
proliferation and islet mass.
Considering the paramount role Cdk4 plays in regulating -cell proliferation
(Rane et al, 1999; Tsutsui et al, 1999), examining the expression pattern will further
confirm the proliferative potential of Ku70-/- and Ku70-/-p53p/p -cells. Indeed, western
blot analysis of isolated -cells confirms increased Cdk4 protein expression in both
mutant backgrounds at all time points when compared with age-matched wild-type
controls (Figure 31a). Representative islet sections show increased nuclear localization
of Cdk4 (Figure 31b) corroborating the western data. Further, Cyclin D2 levels were
elevated in Ku70-/- and Ku70-/-p53p/p islets as compared with age-matched wild-type
controls (Figure 31c). Taken in concert with previous data, -cells from Ku70-/- and
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Figure 31. Increased Cdk4 and CyclinD2 expression in Ku70-/- and Ku70-/-p53p/p
islets. (A) Western blot analysis of Cdk4 using protein from pooled purified islets
from three different mice per time point and genotype. β–actin is shown as a loading
control. (B) Representative sections from medium aged mice incubated with an antiCdk4 antibody (brown) and counterstained with H&E. Arrows indicate Cdk4 positive
cells. Magnification 100X. (C) Representative sections from medium aged mice
incubated with an anti-CyclinD2 antibody (brown) and counterstained with H&E.
Arrows indicate CyclinD2 positive cells. Magnification 60X.
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Figure 32. A progressive stabilization of β-catenin in the absence of Ku70.
Representative pancreatic sections from wild-type, Ku70-/-, and Ku70-/-p53p/p (A)
young, (B) medium, (C) old mice were immunostained using an anti-β-catenin
antibody (green), anti-insulin (red), DAPI (blue). Dashed yellow outline indicates
islets. Magnification: 40X. (D) Western blot analysis of isolated islets from medium
aged wild-type, Ku70-/-, and Ku70-/-p53p/p mice probing for β-catenin and β-actin as a
loading control.

Ku70-/-p53p/p show increased proliferation, increasing the islet area over time, resulting
in the hypoglycemic phenotype observed.
5.2.4

The deficiency in Ku70 progressively leads to an increased

stabilization of -catenin
As mentioned above, canonical Wnt signaling regulates pancreatic -cell
proliferation. A hallmark for Wnt activation is the cytoplasmic accumulation of catenin, which eventually migrates into the nucleus to bind/activate the TCF/LEF
transcriptional co-activators to upregulate target genes like Cyclin D1/2 and Cdk4
(Logan & Nusse, 2004). As shown in Figure 32, islet -catenin levels are comprable in
young mutant mice compared with age matched wild-type sections. Although some
nuclear staining is evident, the increase in -catenin levels becomes obvious upon age,
where aged mutant mice (6-7months) show higher levels of both cytoplasmic and
nuclear localization compared to age-matched wild type sections. This is consistent with
reports indicating a normal downregulation of Wnt pathway being downregulated in
wild-type adult pancreas (Murtaugh et al, 2005; Papadopoulou & Edlund, 2005).
Corroborating the immunofluorescent data, we used purified islet protein extracts from
medium wild-type, Ku70-/- and Ku70-/-p53p/p islets and observed an increase in total catenin levels in the absence of Ku70 (Figure 32d). Further, early passage MEFs were
generated and stained for -catenin; while some nuclear localization was observed in
wild-type MEFs, more cells showed stabilized -catenin in the absence of Ku70-/(Figure 33).
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Figure 33. Increased nuclear β-catenin in early passage MEFs absent for Ku70.
Representative fields from wild-type, Ku70-/-, and Ku70-/-p53p/p passage 2 MEFs
immunostained using an anti-β-catenin antibody (green) and DAPI (blue). Left panels
magnification 40X.
Identified cells in dashed yellow outline in right panel;
magnification 100X.
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Figure 34. Ku70 expression in wild-type islets.
(A)Western blot analysis shows high levels of Ku70 in isolated wild-type islets which
slightly increased with age while being completely absent in both Ku70-/- and Ku70-/p53p/p mice. Samples n ≥ 3 mice islets pooled together. (B) Representative
localization of Ku70 expression shows both nuclear and cytoplasmic in a medium
aged WT mouse. Magnification: 40X.

5.2.5 Ku70 expression in pancreatic -cells.
Previously we demonstrated that DNA ligase IV expression was high in isolated
islets (Tavana et al, 2010c). We attributed the elevated expression of DNA Ligase IV to
function in protecting against spontaneous genomic insults caused by intrinsic metabolic
agents, highlighting the prominent role DNA damage repair machinery plays in
protecting pancreatic -cells.

Seeing the high DNA ligase IV expression, we

hypothesized that the NHEJ pathway may be very active in pancreatic -cells. To
analyze the expression of Ku70, we performed a Western blot in purified wild-type and
mutant pancreatic islets. Our results showed that the Ku70 protein is expressed in
pancreatic -cells and expression level slightly increases with age (Figure 34a).
Immunohistochemical staining reveals both cytoplasmic and nuclear localization of
Ku70 correlating with its multiple functions both dependent and independent of NHEJ
and DNA repair (Figure 34b).
5.2.6 Persistent DNA damage observed in the pancreas of Ku70-/- and Ku70-/p53p/p mutant mice.
The high expression level of DNA ligase IV in pancreatic islets previously lead
us to predict and confirm that DNA damage progressively accumulates in pancreatic
islets of Lig4-/-p53p/p mice (Tavana et al, 2010c). To determine whether H2AX foci, a
prominent marker representing DNA damage, is present in Ku70-/- and Ku70-/-p53p/p
islets, we stained mutant pancreatic sections and compared to age-matched wild-type
controls. As shown in Figure 35, H2AX foci and pan staining was abundantly present in
aged mutant mice, but not in the wild-type mice sections. Additionally, young mutant
pancreatic sections showed few H2AX positive -cells compared to none observed in
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Figure 35. Accumulation of γH2AX in Ku70-/- and Ku70-/-p53p/p islets.
Representative pancreatic sections from wild-type, Ku70-/-, and Ku70-/-p53p/p mice at
different ages were stained using an anti-γH2AX antibody (green), anti-insulin
antibody (red), and DAPI (blue). Magnification: 60X
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Figure 36. Absence of apoptosis in Ku70-/- and Ku70-/-p53p/p islets.
Pancreatic sections from medium mutant and age-matched wild-type controls were
analyzed with a TUNEL assay; no apoptotic cells were detected in the islets, while
Ku70-/- spleen was used as a positive control. Magnification: 60X.

wild-type sections. These results indicate that, like the Lig4-/-p53p/p mutant mice, in the
absence of classical NHEJ, pancreatic islets suffer from the persistence of unrepaired
DNA damage.
5.2.7 Increased expression of p53 and p21 triggers cellular senescence and not
apoptosis in the pancreas of Ku70-/- and Ku70-/-p53p/p mutant mice.
It is well appreciated that persistent DNA damage from NHEJ deficiency triggers
p53-mediated apoptosis in the lymphoid system. We previously did not detect any
apoptosis in the Lig4-/-p53p/p mutant islets (Tavana et al, 2010c) ruling out p53independent apoptosis, but since the Lig4 deficiency presents embryonic lethality (Frank
et al, 1998), we could not accurately assess the role of p53-mediated apoptosis in -cells
after persistent DNA damage. Therefore, utilizing the Ku70 deficiency, we originally
hypothesized to detect apoptosis in this mutant background while not detecting any
apoptosis in the Ku70-/-p53p/p mutant mice. Interestingly, using a TUNEL assay, no
apoptosis was detected in either Ku70-/- or Ku70-/-p53p/p islets, while very low levels
were detected in wild-type sections as compared to a Ku70-/- spleen (Figure 36).
Further, after 10 grays of gamma irradiation, neither wild-type nor Ku70 deficient islets
showed elevated levels of apoptosis after 24 hours (data not shown). In aggregate, these
data indicate that in the presence of DNA damage, pancreatic -cells do not under
apoptosis.
The accumulation of spontaneous unrepaired DNA damage in the Lig4-/-p53p/p cells triggered p53 to transactivate p21 as shown through immunohistochemistry
(Tavana et al, 2010c). To more quantitatively detect p53 and p21 levels in wild-type,
Ku70-/- and Ku70-/-p53p/p islets, Western blot analysis was performed on pooled isolated
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Figure 37. Elevation of p53 and p21 in both Ku70-/- and Ku70-/-p53p/p islets.
(A) Western blot analysis of p53 and p21 using protein from pooled purified islets
from three different mice per time point and genotype. GAPDH is shown as a loading
control. (B) Representative sections from medium aged mice incubated with an antip53 antibody (brown) and counterstained with H&E to validate the western blot.
Arrows indicate p53 positive cells. Magnification 100X.

islet samples. As show in Figure 37a, mutant mice expressed higher levels of p53 when
compared to wild-type at all ages, and was predominantly localized to the nucleus Figure
37c. Interestingly, the expression of p21 initially was elevated in young mutant mice
when compared against wild-type. Although still higher than wild-type, p21 levels in
mutant mice decreased in medium aged mice and slightly increased with age Figure 37b.
Activated p53-p21 promotes cellular senescence in Lig4-/-p53p/p mice as a
mechanism to suppress tumorigenesis not only in the lymphoid system (Van Nguyen et
al, 2007) but also in the pancreatic -cells, which suppressed insulin production in many
islets (Tavana et al, 2010c). We next asked if the DNA damage induced p53/p21
activation was also triggering cellular senescence in Ku70-/- and Ku70-/-p53p/p islets. To
better visualize the -galactosidase expression, a common marker indicating cellular
senescence, pancreatic sections were stained with glucagon after detection of galactosidase. As shown in Figure 38, few islets in young mutant mice showed cellular
senescence; in contrast, many older mutant islets underwent cellular senescence.
Interestingly, unlike Lig4-/-p53p/p islets (Tavana et al, 2010c), insulin production was not
affected in senescent islets as shown through immunohistochemical staining Figure 38.
No senescent cells were detected in age-matched wild-type pancreatic sections.
Remarkably, although the persistent DNA damage activates p53/p21-induced cellular
senescence, preventing tumorigenesis, both Ku70-/- and Ku70-/-p53p/p mice still present
heightened -cell proliferation, increased insulin production and hypoglycemia.

WT

Ku-/-

Ku-/-PP

Y

O

O
12µm

Figure 38. Presence of cellular senescence Ku70-/- and Ku70-/-p53p/p islets.
Pancreatic sections from young and old mutant and age-matched wild-type controls
were stained for β–galactosidase, indicative of cellular senescence, then against
glucagon (brown). Very little cellular senescence is detected in young islets while
both old Ku70-/- and Ku70-/-p53p/p islets show marked upregulation of senescence and
very little detected in old wild-type islets. Bottom panels indicate that Ku70-/- and
Ku70-/-p53p/p islets do not lose the ability to produce insulin upon senescence.
Magnification: 60X.

5.3

Discussion:
In this study, we have shown that Ku70, known best for its role in DNA end

recognition during NHEJ DNA repair, has an important function in β-cell replication.
More specifically, the deficiency of Ku70 results in augmented islet mass, which
increases the insulin production driving progressive hypoglycemia.

Mechanistic

analysis revealed a progressive stabilization of β-catenin, and subsequent activation of
TCF4. This was complimented with increased markers for β-cell proliferation—PCNA,
cyclin D2 and CDK4.

Interestingly, the DNA damage-induced cellular senescence

prevented any islet hyperplasia or tumorigenesis, but failed to inhibit the hypoglycemia.
This was in stark contrast to our previous findings in the Lig4-/-p53p/p mice, where the
DNA damage-induced islet senescence led to β-cell attrition and decreased insulin
production, deregulating glucose homeostasis, resulting in the severe diabetic phenotype
(Tavana et al, 2010a). The similarities of these phenotypes converge on the deficiency
in NHEJ, where spontaneous DNA damage progressively accumulates inducing a p53mediated response halting the β-cell cycle. Therefore, the most obvious difference
between these phenotypes is present early in the absence of Ku70, where the β-cells
show increased proliferation, escaping cell cycle control. These results allowed us to
dissociate Ku70’s function in the β-cell from solely a role in the conventional NHEJdependent DNA repair process as seen in the deficiency of Ligase IV.
Many reports have linked Ku70 to transcriptional regulation either by directly
binding to DNA or indirectly through protein-protein interaction (Brenkman et al, 2010;
De Zio et al, 2010; Giffin et al, 1996; Grote et al, 2006; Idogawa et al, 2007; Lebrun et al,
2005; Nolens et al, 2009). Of particular interest to the present study, researchers have

found that Ku70 may help regulate Wnt signaling upon DNA damage (Idogawa et al,
2007).

Briefly, canonical Wnt signaling is centered around β-catenin-dependent

transcription and activation of TCF/LEF target genes. In the absence of Wnt signaling,
the destruction complex—composed of adenomatous polyposis coli protein (APC), Axin,
casein kinase Iα (CKIα), and glycogen synthase kinase 3β (GSK-3β)—binds and targets
β-catenin for degradation. Wnt signaling regulates many embryonic developmental
events as well as processes to maintain tissue homeostasis, including controlling cellular
proliferation (Logan & Nusse, 2004). Many reports have linked defective Wnt signaling,
though genetic ablation of Wnt signaling components, to a lose in glucose homeostasis
and diabetes while overactive Wnt signaling has been shown to drive β-cell proliferation
and increased insulin secretion (reviewed in (Welters & Kulkarni, 2008)). Consistent
with this notion, researchers constitutively activated β-catenin specifically in islets, and
observed β-cell proliferation rates significantly increase along with elevated insulin
levels (Rulifson et al, 2007). Further, inducing islet-specific β-catenin increased β-cell
proliferation by 2.5 fold in adult mice (Heiser et al, 2006). Conversely, β-catenin
inactivation resulted in islet hypoplasia (Dessimoz et al, 2005). Overexpressing Axin in
islets, inhibiting β-catenin activity, greatly impaired β-cell proliferation (Rulifson et al,
2007). Additionally, perturbing β-catenin activity either by overexpression GSK-3β (Liu
et al, 2008) or by deleting the Wnt co-receptor LRP5 (Fujino et al, 2003), led to
decreased β-cell proliferation and glucose intolerance. Lastly, variants in TCF7L2 (also
known as TCF4) have been identified as a strong risk factor for type 2 diabetes (Grant et
al, 2006) while abolishing TCF7L2 in vitro leads to decreased β-cell proliferation (Shu
et al, 2008). Collectively, these studies emphasize the importance of Wnt signaling in

controlling β-cell proliferation—activated Wnt signaling drives β-cell proliferation and
increases insulin production, while attenuated Wnt signaling decreases β-cell
proliferation.
Previously, researches identified Ku70 as a novel inhibitor of the β-catenin/TCF4
complex; more specifically, Ku70 physically binds to and inhibits TCF4 activation
(Idogawa et al, 2007). Further, when Ku70 was abrogated, canonical Wnt signaling
increased. Conversely, upon DNA damage induction, Ku70 levels increased, and TCF4
activation was ameliorated, evidenced by a decrease in putative downstream targets.
Finally, this regulation was completely independent of Ku80 levels (Idogawa et al, 2007).
These findings explain our data shown in Figures 32 and 33, where activation of Wnt
signaling was observed in the absence of Ku70. It is commonly accepted that Ku70-/MEFs prematurely senesce due to an accumulation of DNA damage and subsequent
activation of the DNA damage response (Gu et al, 1997; Li et al, 1998). Yet in early
passage MEFs, ameliorating Ku70 actually heightens proliferation compared to wildtype as well as rescues growth defects observed in telomere shelterin complex deficient
mice. Further, this proliferation rescue was independent of p53 and ATM (Akhter et al,
2010; Lam et al, 2010). These data, combined with our findings, demonstrate that initial
activation of Wnt signaling occurs in the absence of Ku70 increasing proliferation until
the DNA damage accumulation becomes to excessive and prematurely activates p53mediated cell cycle arrest preventing tumorigenesis. DNA damage-induced senescence
has been previously shown to inhibit tumorigenesis in CKIα deficient gut (Elyada et al,
2011). As mentioned above, Ku70 is triggered upon DNA damage and can inhibit the
activation of TCF4 (Idogawa et al, 2007); applied to our Lig4-/-p53p/p model, therefore,

the accumulating islet-specific DNA damage should activate Ku70 to inhibit Wnt
signaling in concert with cell cycle arrest to halt β-cell proliferation, leading to the
diabetic phenotype observed.

Our proposed model is depicted in Figure 39.

Interestingly, similar to many models of over-activated Wnt signaling, both Ku70-/- and
Ku70-/-p53p/p mice show stabilized β-catenin in the columnar epithelial cells of the colon
accompanied with high-grade dysplasia and adenocarcinoma

(Puebla-Osorio and Zhu

unpublished data). Further investigation is currently ongoing to elucidate the precise
mechanism Ku70 functions in suppressing canonical Wnt signaling.
Complimenting the increased β-cell proliferation data, we observed an early and steady
elevation in Cdk4 levels (Figure 31). This is not surprising, considering that Cdk4
regulation is paramount to controlling β-cell proliferation (Martin et al, 2003; Mettus &
Rane, 2003; Rane et al, 1999; Tsutsui et al, 1999). Interestingly, a constitutively active
Cdk4 mutant, Cdk4R24C, presented a stark increase in β-cell proliferation and augmented
islet mass leading to islet hyperplasia and in some cases, insulinomas (Hino et al, 2004;
Rane et al, 1999). This increase in islet proliferation was enough to rescue previously
established diabetic models (Miyawaki et al, 2008), collectively placing Cdk4 as a
central β-cell regulator. Further, Sushil Rane’s group recently revealed that Cdk4 not
only promotes quiescent adult β-cells into proliferation, but also activates early β-cell
progenitors in the ductal epithelium (Lee et al, 2010).

Further characterization of

elevated Cdk4 levels in the embryonic pancreas, using the Cdk4R24C mutant, showed
increased proliferation and expansion of early mesenchymal endocrine precursors during
pancreatic development (Kim & Rane, 2011). These studies underscore pivotal roles for
Cdk4 both during embryogenesis by regulating pancreatic progenitors and adult

Figure 39. Proposed schematic depicting the outcome of β-cells after DNA
damage. When pancreatic β-cells encounter spontaneous or induced DNA double
strand breaks, the non-homologous end joining pathway is activated to repair the
broken DNA. In the wild-type background, DNA is repaired and β-cell proliferation
returns to normal. Deficiency of proteins solely responsible for DNA repair in the
NHEJ pathway (as in Lig4-/-), result in an accumulation of unrepaired DNA breaks
which permanently halts the β-cell cycle decreasing islet mass and driving
hyperglycemia/diabetes. Deletion of proteins involved in the NHEJ pathway that
have additional roles outside of DNA repair (as in Ku70-/-) result in an accumulation
of unrepaired DNA breaks without initially arresting the β-cell cycle which results in
uncontrolled β-cell proliferation and hypoglycemia. Cellular senescence is induced
to suppress tumorigenesis.

β-cell regeneration by controlling the β-cell cycle.

Taken together, it is therefore

tempting to speculate that the elevated Cdk4 expression seen in both Ku70 -/- and Ku70-/p53p/p islets could be contributing not only to increasing adult β-cell proliferation, but
also increasing the β-cell progenitor pools allowing for increased β-cell differentiation
and augmented islet mass. Additionally, the presence of DNA damage and an activated
DNA damage response protects against the formation of insulinomas, but not from
hypoglycemia. Further mechanistic investigation must be preformed to test this theory,
which is currently ongoing. Nevertheless, our study highlights the importance function
of Ku70, independent of the DNA repair ability in the non-homologous end joining
pathway, in the regulation of pancreatic β-cell proliferation.

CHAPTER 6
FUTURE DIRECTIONS

The insights gained from this dissertation suggest that cellular senescence is a
formidable barrier against tumorigenesis, although it comes at a cost. The utilization of
the hypomorphic, separation-of-function, mutant p53, p53p/p, suggests that in the absence
of p53-mediated apoptosis, cell cycle arrest can act in parallel to apoptosis in preventing
genomic instability. Our study exposing mice to UVB radiation demonstrates that the
hypomorphic p53p/p mutation leads to UVB hypersensitivity in vivo and in vitro. These
mutant mice showed less tolerance to UVB radiation; low doses of radiation caused
severe skin swelling and higher immunosuppression compared to wild-type mice.
However, this was independent to changes in repairing the UV-induced damage,
indicating that the increased susceptibility results specifically from UV-induced cellular
responses (Chapter 3) (Tavana et al, 2010a). Interestingly, reduced immunosuppression
has been identified as a major risk factor for the induction to cancers (Beissert & Loser,
2008). It would be interesting to test if the downstream effects of DNA damage, namely
cellular senescence, cause this immunosuppression.

We would need to generate

p53p/pp21-/- mice and analyze their response to low doses of UVB. This would directly
reveal if cellular senescence is the cause of the immunosuppression and hypersensitivity
seen in the p53p/p background, as p53p/pp21-/- mice basically phenocopy p53-/- (Barboza
et al, 2006). Interestingly, along with other reports, we have shown that the p53p/p
mutant cannot transactivate critical downstream apoptotic markers yet retains the ability
to partially upregulate p21, responsible for cell cycle arrest.

This mechanism still

remains unknown, and would be relevant to other p53 mutants that have this inability
and directly drive cancer formation. A clue may lie in the nature of promoters that p53
directly regulates. A study showed that the kinetics of genes involved in cell cycle

regulation have “preloaded” promoters and can be activated much faster than the
apoptotic molecules that need to assemble and activate the pre-initiation complex
(Morachis et al, 2010).

This may explain why p53p/p has the ability to partially

transactivate p21 while apoptotic genes cannot be activated. Further, the introduction of
a proline amino acid may slightly alter the DNA binding ability of certain genes that
present much stricter protein stoichiometry than other sites. This can explain why the
p53h/h mutant cannot even transactivate p21. Nevertheless, further studies are needed to
understand exactly why the hypomorphic p53p/p cannot transactivate apoptotic molecules
yet retains a partial ability to activate cell cycle regulators.
In regards to the presence of spontaneous double strand breaks in the p53p/p
background, utilizing the deficiency in DNA ligase IV, we showed that the nonhomologous end pathway has a previously overlooked function in protecting DNA
damage in the pancreatic β-cells (Chapter 4). We have shown that the presence of
endogenous DNA breaks can permanently halt the cell cycle in a p53/p21-dependent
manner, which decreases the number of proliferating β-cells and decreases the mass of
islets. Ultimately, islet involution lowers the levels of secreted insulin, because less cells
have the ability to make insulin, and causes dysregulated glucose homeostasis and
diabetes (Tavana et al, 2010c). We noted an increased level of DNA ligase IV in
isolated pancreatic β-cells, yet the deficiency in DNA ligase IV leads to embryonic
lethality. To further study the role of DNA ligase IV in the pancreatic β-cell, it would be
interesting to generate an islet specific knock-out, using a RIP-Cre mouse; this would
allow for the analysis of wild-type p53 function after severe DNA damage (more severe
than the Ku70-/- observed in Chapter 5).

Further, because the Lig4-/-p53-/- mice

succumb to aggressive lymphomas around 2 months of age (Zhu et al, 2002), it would be
interesting to take the conditional Lig4 mouse and cross it to a p53 deficiency to see if
genomic instability occurs leading to islet tumorigenesis. Other than Ku70, we have not
analyzed other levels of NHEJ factors in the islets, nor characterized their phenotypes.
In Chapter 5, we unexpectedly showed that the deficiency for Ku70 leads to
increased β-cell proliferation and augmented islet mass. This caused stark elevations in
secreted insulin levels, which drove the hypoglycemic phenotype observed. The driving
force behind this augmented proliferation was the stabilization of the Wnt signaling
pathway in the absence of Ku70. Unlike the Lig4-/-p53p/p mutant, the induction of
cellular senescence prevented β-cell neoplasia and islet tumorigenesis.

The most

interesting finding in this study is the relationship between Ku70 and Wnt signaling,
underscoring a NHEJ-independent function of Ku70. Very few reports have identified
any connection between these two pathways; one in particular has identified Ku70 as a
novel competitive antagonist to TCF4 (Idogawa et al, 2007), the transcription factor
responsible for activating many downstream targets involved in cellular proliferation as
well as many other processes. Researchers further showed that DNA damage increases
the levels of Ku70, which lead to a decrease in TCF targets, suggesting that Ku70
inhibits β-catenin/TCF4 binding. Our results indicate that in the absence of Ku70, Wnt
signaling is stabilized—namely, β-catenin levels are elevated and eventually translocate
into the nucleus. A few possible scenarios may explain the involvement of Ku70 in Wnt
signaling: 1. Ku70 directly binds to β-catenin inhibiting the translocation into the
nucleus, so in the absence, β-catenin can more readily enter the nucleus and activate
TCF4; 2. Ku70 may facilitate the destruction complex responsible for degrading β-

catenin, where in the absence of Ku70 the destruction complex is less effective; 3. Ku70
either binds to the Wnt ligand or the receptor responsible for activating Wnt signaling.
These are three possible hypotheses of direct Ku70 interaction with Wnt signaling; it is
very likely that the relationship is indirect. Recently, researchers have identified Tert as
a novel modulator of Wnt signaling (Park et al, 2009). This regulation occurs along side
Smarcal, a gene involved in the DNA damage response. Therefore, it is plausible that
Ku70 either interacts with Tert or Smarcal1 to negatively regulate Wnt signaling.
Reports have already identified Ku70 to directly interact with Tert, although the
interaction with Smarcal remains elusive.

Nevertheless, it is important to

mechanistically identify the role of Ku70 and canonical Wnt signaling. Lastly, we are
proposing that Ku70 may be used as a therapeutic target to coax β-cells into proliferating,
alleviating the major problem in some patients with type 2 diabetes mellitus.

To

strengthen this suggestion, we propose to cross Ku70 deficiency with other models that
lead to type 2 diabetes due to a decrease in islet proliferation. One perfect model for this
is our Lig4-/-p53p/p model (Tavana et al, 2010c).

Dr. Lieber’s group has already

generated Lig4-/-Ku70-/- mice, and shown that the deficiency in Ku70 is sufficient
enough to rescue the lethality from Lig4-/- (Karanjawala et al, 2002). Unfortunately,
proliferation rates were not analyzed and this group speculated that the absence of Ku70
rendered any function of Lig4 ineffective because Ku70 is upstream in the NHEJ
pathway. Since this group observed no changes in apoptosis levels, an alternative
interpretation to their findings is that the deficiency of Ku70 increases proliferation of
certain cell types, rescuing the lethality caused by the excessive apoptosis. Generating
Ku70-/-Lig4-/-p53p/p mice will allow us to analyze the function of Ku70 in the recovery of

β-cell proliferation. Also, other models (described in (Tavana & Zhu, 2011)) may be
used for further validation. Further work is needed to elucidate this puzzle. Taken in
aggregate, this work portrays that the function of cell cycle arrest in the presence of
DNA damage prevents tumorigenesis, but comes at a cost.
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